WO2013142365A1 - Procédés et dispositifs de refroidissement systémique et cérébral non invasif alternant une brume de liquide/du gaz pour l'induction et de gaz pour la maintenance - Google Patents

Procédés et dispositifs de refroidissement systémique et cérébral non invasif alternant une brume de liquide/du gaz pour l'induction et de gaz pour la maintenance Download PDF

Info

Publication number
WO2013142365A1
WO2013142365A1 PCT/US2013/032379 US2013032379W WO2013142365A1 WO 2013142365 A1 WO2013142365 A1 WO 2013142365A1 US 2013032379 W US2013032379 W US 2013032379W WO 2013142365 A1 WO2013142365 A1 WO 2013142365A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid
patient
cooling
temperature
gas
Prior art date
Application number
PCT/US2013/032379
Other languages
English (en)
Inventor
Allan Rozenberg
Original Assignee
Benechill, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/423,561 external-priority patent/US9358150B2/en
Application filed by Benechill, Inc. filed Critical Benechill, Inc.
Publication of WO2013142365A1 publication Critical patent/WO2013142365A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/12—Devices for heating or cooling internal body cavities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/12—Devices for heating or cooling internal body cavities
    • A61F7/123—Devices for heating or cooling internal body cavities using a flexible balloon containing the thermal element
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/04—Tracheal tubes
    • A61M16/0434—Cuffs
    • A61M16/0436—Special fillings therefor
    • A61M16/0438—Liquid-filled
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/04—Tracheal tubes
    • A61M16/0434—Cuffs
    • A61M16/0443—Special cuff-wall materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M19/00—Local anaesthesia; Hypothermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0001—Body part
    • A61F2007/0002—Head or parts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0001—Body part
    • A61F2007/0002—Head or parts thereof
    • A61F2007/0006—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0054—Heating or cooling appliances for medical or therapeutic treatment of the human body with a closed fluid circuit, e.g. hot water
    • A61F2007/0056—Heating or cooling appliances for medical or therapeutic treatment of the human body with a closed fluid circuit, e.g. hot water for cooling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0054—Heating or cooling appliances for medical or therapeutic treatment of the human body with a closed fluid circuit, e.g. hot water
    • A61F2007/0056—Heating or cooling appliances for medical or therapeutic treatment of the human body with a closed fluid circuit, e.g. hot water for cooling
    • A61F2007/0057—Heating or cooling appliances for medical or therapeutic treatment of the human body with a closed fluid circuit, e.g. hot water for cooling of gas, e.g. air or carbon dioxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0059—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit
    • A61F2007/006—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit of gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0059—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit
    • A61F2007/0063—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit for cooling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0059—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit
    • A61F2007/0063—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit for cooling
    • A61F2007/0064—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit for cooling of gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/04—Tracheal tubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/04—Tracheal tubes
    • A61M16/0402—Special features for tracheal tubes not otherwise provided for
    • A61M16/0409—Special features for tracheal tubes not otherwise provided for with mean for closing the oesophagus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/04—Tracheal tubes
    • A61M16/0475—Tracheal tubes having openings in the tube
    • A61M16/0477—Tracheal tubes having openings in the tube with incorporated means for delivering or removing fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/04—Tracheal tubes
    • A61M16/0486—Multi-lumen tracheal tubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06—Respiratory or anaesthetic masks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/20—Valves specially adapted to medical respiratory devices
    • A61M16/208—Non-controlled one-way valves, e.g. exhalation, check, pop-off non-rebreathing valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/20—Valves specially adapted to medical respiratory devices
    • A61M16/208—Non-controlled one-way valves, e.g. exhalation, check, pop-off non-rebreathing valves
    • A61M16/209—Relief valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3368—Temperature
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/36—General characteristics of the apparatus related to heating or cooling
    • A61M2205/3606—General characteristics of the apparatus related to heating or cooling cooled
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/75—General characteristics of the apparatus with filters
    • A61M2205/7545—General characteristics of the apparatus with filters for solid matter, e.g. microaggregates

Definitions

  • the invention relates to cerebral and systemic cooling via the nasal cavity, oral cavity, and other parts of the body, and more particularly to methods and devices for cerebral and systemic cooling using liquids or liquid mists w th boiling points above body temperature and dry gases and for delivering the liquid mists and/or dry gases to the nasopharyngeal cavity.
  • Cerebral ischemia i.e., reduction or cessation of blood flow to the central nervous system, can be characterized as either global or focal Global cerebral ischemia refers to reduction of blood flow within the cerebral vasculature resulting from systemic circulatory failure caused by, e.g., shock, cardiac failure, or cardiac arrest. Within minutes of circulatory failure, tissues become ischemic, particularly in the heart and brain.
  • cardiogenic shock which results from severe depression of cardiac performance.
  • the most frequent cause of cardiogenic shock is myocardial infarction with loss of substantial muscle mass.
  • Pump failure can also result from acute myocarditis or from depression of myocardial contractility following cardiac arrest or prolonged cardiopulmonary bypass.
  • Mechanical abnormalities such as severe valvular stenosis, massive aortic or mitral regurgitation, acutely acquired ventricular septal defects, can also cause cardiogenic shock by reducing cardiac output. Additional causes of cardiogenic shock include cardiac arrhythmia, such as ventricular fibrillation.
  • Cardiac arrest often progresses to death within minutes if active interventions, e.g., cardiopulmonary resuscitation (C.PR), defibrillation, use of inotropic agents and vasoconstrictors such as dopamine, dobutarnine, or epinephrine, are not undertaken promptly.
  • active interventions e.g., cardiopulmonary resuscitation (C.PR)
  • defibrillation e.g., cardiopulmonary resuscitation (C.PR)
  • inotropic agents and vasoconstrictors such as dopamine, dobutarnine, or epinephrine
  • the most common cause of death during hospitalization after resuscitated cardiac arrests is related to the severity of ischemic injury to the central nervous system, e.g., anoxic encephalopathy.
  • the ability to resuscitate patients of cardiac arrest is related to the time from onset to institution of resuscitative efforts, the mechanism, and the
  • Focal cerebral ischemia refers to cessation or reduction of blood flow within the cerebral vasculature resulting in stroke, a syndrome chai-acterized by the acute onset of a neurological deficit that persists for at least 24 hours, reflecting focal involvement of the central nervous system.
  • Approximately 80% of the stroke population is hemispheric ischemic strokes, caused by occluded vessels that deprive the brain of oxygen-carrying blood.
  • Ischemic strokes are often caused by emboli or pieces of thrombotic tissue that have dislodged from other body sites or from the cerebral vessels themselves to occlude in the narrow cerebral arteries more distally.
  • Hemorrhagic stroke accounts for the remaining 20% of the annual stroke population.
  • Hemorrhagic stroke often occurs due to rupture of an aneurysm or arteriovenous inalfomiation bleediiig into the brain tissue, resulting in cerebral infarction.
  • Other causes of focal cerebral ischemia include vasospasm due to subarachnoid hemorrhage from head trauma or iatrogenic intervention.
  • a thrombolytic agent e.g., tissue plasminogen activator (t-PA)
  • t-PA tissue plasminogen activator
  • Treatment with systemic t-PA is associated with increased risk of intracerebral hemorrhage and other hemorrhagic complications.
  • thrombol tic agents and heparin there are no therapeutic options currently on Ihe market for patients suffering from occlusion focal cerebral, ischemia.
  • Vasospasm may be partially responsi e to vasodilating agents.
  • the newly developing field of neurovascular surgery which involves placing minimally invasive devices within the carotid arteries to physically remove the offending lesion, may- provide a therapeutic option for these patients in the future, although this kind of manipulation may lead to vasospasm itself.
  • the nasal cavity might be a site where respiratory evaporative heat loss or convection can significantly affect adjacent brain temperatures, especially because most of the warmthing of inhaled air occurs in the uppermost segment of the airways.
  • the invention relates to methods, devices, and compositions for cerebral cooling, preferably via the nasal and/or oral cavities.
  • the cooling occurs by direct heat transfer through the nasopharynx as well as by hematogenous cooling through the carotids as they pass by the oropharynx and through the Circle of Willis, which lies millimeters away from the pharynx.
  • the direct cooling will be obtained through evaporative heat joss of a nebulized liquid in the nasal cavity, oral cavity, and/or throat. Additionally, cooling may occur through convection in the nasal cavity.
  • cerebral cooling may help to minimize neurologic deficits in treating patients with either stroke or cardiogenic shock caused by reduced cerebral perfusion or in the treatment of migraines.
  • a cooling assembly, device, or method for insertion into a nostril of a patient
  • a second cooling assembly or device can optionally also be inserted into the other nostril to maximize cooling.
  • patient safety by comparison with transpulmonary and intravascular cooling methods and devices.
  • the invention provides a method for cerebral cooling.
  • An elongate member can be inserted into a nasal cavity of a patient tlirough the patient's nostril.
  • the elongate member has a proximal end, a distal end, a first lumen extending therebetween, and a plurality of ports in fluid communication with the first lumen.
  • This device can be used to alternate between delivery of a wet gas (nebulized liquid coolant and a substantially dry gas) and dry gas (substantially dry gas substantially free of liquid) for nasal cooling.
  • a nebulized liquid coolant and a substantially dry gas are then delivered in combination onto a surface of the patient's nasal caviiy through the plurality of ports in the elongate member for a period of between about 10 minutes to 9 hours.
  • a substantially dry gas substantially free of liquid is then delivered onto a surface of the patient's nasal cavity through the plurality of ports in the elongate member for a period of between about 10 minutes to 240 hours.
  • the liquid coolant is nebulized at the plurality of ports within the nasal cavity and the delivery of the substantially dry gas in combination with the nebulized liquid coolant enhances evaporation of the liquid coolan t from the nasal cavity to reduce the cerebral temperature of the patient.
  • the e vaporation of the liquid coolant in the nasal cavity which is enhanced b the substantially dry gas, results in reduction of the cerebral temperature of the patient by between about 0.1 to 5.0 ° C hr.
  • the step of delivering the substantially dry gas substantially free of a liquid is administered first to reduce the patient's cerebral temperature and the step of delivering a nebulized liquid coolant and a substantially dry gas in combination initiated subsequently to further reduce the patient's cerebral temperature to between about 1 8 to 36°C.
  • the method may further include repeating the step of deli vering a substantially dry gas substantially free of a liquid onto the surface of the patient's nasal cavity through the plurality of ports in. the elongate member for a period of between about 10 minutes to 10 days to prevent rewamiing of the cerebral temperature of the patient.
  • repeating the step of delivering a substantially dry gas substantially free of a liquid onto the surface of the patient's nasal cavity may be initiated when the patient's brain has been cooled to a temperature of about ] 8 to 36 "C
  • the method may further comprise repeating the step of delivering a nebulized liquid coolant and a substantially dry gas in combination onto a surface of the patient's nasal cavity for a period of between about 10 minutes to 9 hours to maintain a cerebral temperature of between about 18 to 36°C
  • the method may be used for about 6 hours while the patient is transitioning from nasal cooling to systemic cooling, such as surface cooling or intravascular cooling
  • the gas may be dry air or one of its components.
  • the gas may be oxygen, a noble gas, or an anesthetic agent.
  • the gas may be delivered at a rate of between about 20 to lOOL/min.
  • the liquid coolant may be a peril uorocarbon.
  • the perflisorocarbon may have a boiling point above 37 ° C, alternatively between about 0°C and about 160°C, alternatively between about 25'C and about 140 'C.
  • the invention provides an alternative method for cerebral cooling.
  • An elongate member can be inserted into a nasal cav ity of a patient through a patient's nostril.
  • the elongate member may have a proximal end, a distal end, a first lumen extending therebetween, and a plurality of ports in fluid communication with the first lumen.
  • a nebulized liquid coolant and a substantially dry gas are can be delivered in combination onto a surface of the patient's nasal cavity through the plurality of ports in the elongate member for a period of between about 10 minutes to 9 hours, 'The liquid coolant is nebulized at the plurality of ports within the nasal cavity and the gas enhances evaporation of the liquid coolant from the nasal cavity to further reduce the cerebral temperature of the patient,
  • a substantially dry gas substantially free of liquid can be delivered onto a surface of the patient's nasal cavity through the plurality of ports in the elongate member for a period of between about 10 minutes to 10 days.
  • the patient's temperature can be measured and the delivery of the nebulized liquid coolant can be adjusted in response to the patient's temperature.
  • the patient's temperature may be measured by measuring one of the patient's cerebral temperature, esophageal temperature, tympanic temperature, body temperature, bladder temperature, blood temperature, or rectal temperature.
  • the step of measuring the patient's temperature may further comprise continuously monitoring the patient's core temperature.
  • the delivery of the nebulized liquid coolant can be stopped in response to the patient's temperature. Delivery of the nebulized liquid coolant in combination with the substa ially dry gas can then be repeated for a period of between about 10 minutes to 9 hours to prevent rewarming of the cerebral temperature of the patient.
  • some embodiments further comprise the step of setting a target temperature for the core temperature of no lower than 30°C, and then delivering the nebulized liquid coolant and a substantially dry gas in combination onto the surface of the patient's nasal cavity until the core temperature reaches the target temperature. For example, an operator may set the target core temperature within the range of about 30 to 37 °C.
  • the step of delivering a substantially dry gas substantially free of a liquid onto a surface of the patient's nasal cavity can then be automatically repeated when the patient's core temperature reaches the target temperature
  • the step of delivering a nebulized liquid coolant and a substantially dry gas in combination onto a surface of the patient's nasal cavity can be automatically repeated when the patient's core temperature rises more than 0.1 °C above the target temperature.
  • the step of adjusting delivery of the nebulized liquid coolant can comprise repeating delivery of the nebulized liquid coolant and a substantially dry gas in combination onto a surface of the patient's nasal cavity when the patient's core temperature reaches substantially greater than the target temperature
  • a target temperature for the patient's cerebral temperature can be set within a range of about 18-36°C
  • the step of delivering the nebulized liquid coolant and a substantially dry gas in combination may further comprise intermittently delivering a nebulized liquid coolant and substantially dry gas in combination onto the surface of the patient's nasal cavity to maintain the patient's cerebral temperature within ⁇ 0.5°C of the target temperature.
  • the step of delivering the substantially dry gas substantially free of a liquid is administered first to reduce the patient's cerebral temperature and the step of delivering a nebulized liquid coolant and a substantially dry gas in combination can then be initiated subsequently to further reduce the patient's cerebral temperature to a temperature of between about 30 to 36°C.
  • the step of delivering a substantially dry gas substantially free of a liquid onto a surface of the patient's nasal cavity may then be repeated for a period of between about 10 minutes to 10 days to maintain a cerebral temperature of between about 18 to 36°C.
  • a medical device for cerebral cooling comprises an elongate tubular member capable of delivering a gas only or a gas in combination with a liquid coolant to a patient's nasal cavity, a liquid coolant source, a compressed gas source, and a switch for alternately connecting the liquid coolant source.
  • the elongate tubular member has proximal and distal ends and an outer wall having a plurality of delivery ports.
  • First and second lumens extend from a proximal region of the elongate tubular member to the delivery ports and are in fluid communication with the delivery ports,
  • the gas source is in fluid communication with the first lumen and the switch alternately connects the liquid coolant source to the second lumen so that the first lumen transports a compressed gas to the delivery ports and the second lumen transports a liquid coolant to the delivery ports, in some embodiments, a plurality of mixing channels extend between the plurality of delivery ports and the first lumen and a plurality of connecting tubes extend between the mixing channels and the second lumens.
  • the first and second lumens are arranged such that in use the liquid coolant and compressed gas are separately transported from the proximal end of the elongate tubular member to the plurality of deliver ports on the outer wall.
  • the invention provides a method for cerebral cooling, An elongate member can be inserted into a nasal cavity of a patient through the patient's nostril.
  • the elongate member may have a proximal end, a distal end, a first lumen extending therebetween, and a plurality of ports in fluid
  • a substantially dry gas is then delivered onto a surface of the patient's nasal cavity through the plurality of ports in the elongate member at a flow rate of between about 20 to lOOL/min. In some embodiments, the method may occur for about 6 hours when the patient is transitioning from nasal cooling to surface or intravascular cooling.
  • the invention includes an elongate tubular member having an outer wall, proximal and distal ends, and first and second lumens.
  • the outer wall has a plurality of delivery ports that are located along the elongate tubular member and a plurality of mixing channels extending between said plurality of delivery ports and the first lumen.
  • a plurality of connecting tubes extends between the plurality of mixing channels and the second lumen.
  • a switch is operably connected to the first lumen.
  • the first lumen extends between the proximal and distal ends of the elongate tubular member and transports a liquid having a boiling point between about 38°C and about 300°C
  • the second lumen extends between the proximal and distal ends of the elongate tubular member and transports a compressed gas.
  • the first and second lumens are arranged such that in use the liquid and compressed gas are separately transported from the proximal end to the plurality of delivery ports of the elongate tubular member, and the switch operates to establish and interrupt flow of the liquid from a source of the liquid to the first lumen.
  • the invention in another alternative embodiment, includes an elongate tubular member having an outer wall, proximal and distal ends, and first and second lumens extending therebetween.
  • the outer wall has a plurality of delivery ports that are located along the elongate tubular member.
  • a plurality of mixing channels extends between the plurality of delivery ports and the first lumen.
  • a plurality of connecting tubes extends between the plurality of mixing channels and the second lumen.
  • the invention also includes a compressed gas source and a liquid source having a liquid with a boiling point between about 38°C and about 300°C.
  • a switch is operably connected to the liquid source and the second lumen of the elongate tubular member.
  • the compressed gas source is operably connected to the proximal end of the second lumen and the liquid source is operably connected to the proximal end of the first lumen for separately delivering a gas and a liquid from the proximal end of the elongate tubular member to the plurality of delivery ports.
  • the switch operates to establish and interrupt flow of the liquid from the liquid source to the first lumen.
  • the invention in another alternative embodiment, includes an elongate tubular member having proximal and distal ends, an outer wall having a plurality of delivery ports, and first and second lumens.
  • the first and second lumens extend from a proximal region to the delivery ports and are in communication with the plurality of delivery ports.
  • the invention also includes a source of liquid coolant, a gas source in fluid communication with the first lumen, and a switch for alternately connecting the liquid coolant source to the second lumen.
  • the first lumen transports a compressed gas and wherein the second lumen transports a volatile liquid.
  • the volume of liquid delivered may range from about 0, 1 to about 20 liters, alternatively about 1 to about 20 liters, alternatively about 1 to about 15 liters, alternatively about 1 to about 10 liters, alternatively about 1 to about 8 liters, alternatively about 2 to about 6 liters,
  • Unevaporated liquid may also be suctioned or otherwise removed from the patient's nasal pharynx.
  • a cooling helmet may also be used to help lower the cerebral temperature of the patient.
  • a warming blanket may be used to maintain the systemic temperature of the patient, or prevent the systemic temperature from decreasing as much as t eh cerebral temperature.
  • a vasodilator may also be delivered to the patient's nasal cavity to enhance vascular cooling capacity.
  • a humidifier such as isotonic saline or water
  • a humidifier may also be delivered into the patient's nasal cavity. Additional air or oxygen may be delivered to the patient to enhance the evaporative process through a mask placed over the nose of the patient, such as a CPAP nasal mask.
  • the patient's cerebral, systemic, and nasal temperatures may also be monitored during this method.
  • the nebulized spray may be delivered at a flow rate sufficient to achieve a gradient of not greater than about 0.5'C between the outer surface of the brain and the inner core of the brain.
  • the nebulized spray may also be delivered at a flow rate sufficient to achieve a gradient of at least about l . 'C between the cerebral temperature and the systemic temperature.
  • the nebulized spray may also be delivered at a flow rate sufficient to achieve cerebral cooling at a rate greater than about l.CTC in hour,
  • the nebulized spray may also be delivered at a flow rate sufficient to achieve a temperature in the nasal cavity of about 4.0 ° C or less.
  • a nasal catheter may be used to deliver a spray of liquid to the nasal cavity of a patient.
  • the nasal catheter may be placed in the nares of the patient's nose and may be angled to direct the spray outlet at the desired structures of the nose, for example, the nasal conchae.
  • the distal end of the nasal catheter and may be designed to cause the spray to spread in a pattern which will allow the gas and liquid mixture to contact as much of the desired tissue as possible. Spreading the spray will also minimize the potential of medical trauma that could result form a high velocity stream of liquid directed at the tissue of the nasal cavity.
  • the distal end of the catheter may be 'tipped', i.e., sealed of in a rounded fashion to provide a smooth surface to avoid damaging the sensitive nasal tissues,
  • the spray pattern may be formed by creating one or more holes along opposite sides of the catheter tip, which would create a broad, flat spray perpendicular to the axis of the catheter.
  • This pattern may be further altered by changing the size, location and nmnber of holes in the catheter, in addition, this pattern may further include a hole in the tip of the catheter to produce some additional flow in the axial direction.
  • An alternative spray pattern may be formed by making a slit in the tip of the catheter to produce a fan shaped spray centered on the axial direction of the catheter. This pattern maybe further altered by varying the width of the slit and the length the slit extends down the sides of the catheter.
  • multiple, intersecting slits may be made in the catheter tip.
  • Another alternative spray pattern may be formed by making a straight or curved cut along opposite sides of the catheter wall. The skived cut may extend from and include a portion of the tip. This configuration will produce a wide 'fan' shaped spray covering a broad angle from the perpendicular to the axial direction of the catheter.
  • any of the above described patterns could be combined to create additional spray patterns for the nasal catheter.
  • the patient's nasal cavity may be pre-sprayed with an anesthetic, such as lidocaine or neurotensin, to anesthetize the trigeminal nerve endings prior to initiating cooling in order to prevent any sensation of the cooling which could be interpreted by the patient as pain.
  • an anesthetic such as lidocaine or neurotensin
  • compositions of the invention include liquids having a boiling point of between about 38 and about 300 °C. alternatively a boiiing point of between about 38 and about 200 °C, alternatively a boiling point of between about 60 and about 150°C, alternatively a boiling point of between about 70 and about 125°C, alternatively a boiling point of between about 75 and about 1 10°C, alternatively a boiling point of between about 60 and about 70°C.
  • Compounds having suitable characteristics for use herein include hydrocarbons, fluorocarbons, perfluorocarbons, and perfluorohydrocarbons. Saline is another example of a substance having suitable characteristics for use herein. As used in this specification, the terms "fluorocarbon,” “perfluorocarbon,” and
  • perfluorohydrocarbon are synonymous. In addition to containing carbon and fluorine, these compounds may also contain other atoms. In one embodiment, the compounds could contain a heteroatom, such as nitrogen, oxygen, or sulfur, or a halogen, such as bromine or chlorine. These compounds may be linear, branched, or cyclic, saturated or unsaturated, or any combination thereof.
  • the compounds are highly fluorinated compounds, which are compounds containing at least three fluorine atoms. These highly fluorinated compounds may also contain other atoms besides carbon and fluorine. These other atoms include, but are not limited to, hydrogen; heteroatoms such as oxygen, nitrogen, and sulfur; and halogens such as bromine or chlorine, in one embodiment, the number of the atoms that are not carbon or fluorine comprise a minority of the total number of atoms in the compound.
  • These highly fluorinated compounds may be linear, branched, or cyclic, saturated or unsaturated, or any combination thereof. Examples of these compounds include, but are not limited to, C ⁇ F ⁇ B (b.p. 43 °C),
  • the compounds are hydrofluorocarbons, which are compounds where the number of hydrogen atoms exceeds the number of fluorine atoms.
  • These hydrofluorocarbons may also contain other atoms besides hydrogen, carbon, and fluorine. These other atoms include, but are not limited to, heteroatoms such as oxygen, nitrogen, and sulfur and halogens such as chlorine and bromine.
  • hydro fluorocarbons include, but are not limited to, hydrochlorofluorocarbons, more specifically, hydrochlorofluoralkanes.
  • the number of the atoms other than carbon and fluorine comprise a minority of the total number of atoms in the compound.
  • These hydrofluorocarbons may be linear, branched, or cyclic, saturated or unsaturated, or any combination thereof,
  • hydrofluorocarbons light fluorocarbons, hydrocarbons, fluorocarbons, perfluorocarbons, perfluorohydrocarbons, or any of the above-mentioned compounds may also be used.
  • the mixture may contain any of the previously mentioned compounds in different phases (e.g., one gas, one liquid).
  • the mixture has a boiling point above 37 °C, even though any individual component of the mixture may have a boiling point below 37 °C.
  • Light fluorocarbons are fluorocarbons that have a boiling point below 37 °C. These Sight fluorocarbons may also contain other atoms besides carbon, and fluorine. These other atoms include, but are not limited to, hydrogen; heieroatoms such as oxygen, nitrogen, and sulfur; and halogens such as chlorine and bromine.
  • light fluorocarbons include, but are not limited to peril uorobutane and perfluoropentane.
  • the number of the atoms other than carbon and fluorine comprise a minority of the total number of atoms in the compound. These light fluorocarbons may ⁇ be linear-, branched, or cyclic, saturated or unsaturated, or any combination thereof,
  • Nitric oxide or adrenergic agents such as adrenaline (epinephrine) or albuterol, may be added in minute doses to the compositions described in any of the previously described embodiments.
  • the NO or other agent is inhaled and acts as a potent nasal vasodilator, which impro ves the rate of action of the cooling mist and counteracts nasal vasoconstriction caused by administering cold substances to the nasal cavity.
  • the NO may be included in an amount of about 2 to about 80 parts per million, in other cases in an amount of about 3 to about 20 parts per million, in other cases in an amount of about 4 to about 10 parts per million, in other cases in an amount of about 5 to about 8 parts per million, in other cases in an amount of about 5 pails per million.
  • administering preferably a cold dr gas such as dry air or dry heiiox, e.g., a mixture of helium and oxygen.
  • a cold dr gas such as dry air or dry heiiox
  • the gaseous phase in the nasal cavity may become saturated with gaseous PFC, thereby slowing the rate of evaporative heat loss, in order to accelerate the rate of evaporative heat loss, it may be desired to periodically purge the nasal cavity of perfluorocarbon. This can be done by cycling administration of cold mists with administering another gas, preferably a dry gas such as dry air or dry heliox.
  • cycling it is recommended that the cycles occur for about 3 seconds or more, in other cases for about 30 seconds or more, in other cases for about one minute or more, in other cases for about two minutes or more, in other cases for about five minutes or more, in other cases for about ten minutes or more, in other cases for about 30 minutes or more.
  • the intervening cycle of dry gas may last for an equal period (e.g., about 3 seconds of cold mist followed by about 3 seconds of dry gas, about 30 seconds of cold mist followed by about 30 seconds of dry gas, about one minute of cold mist followed by about one minute of dry gas, about two minutes of cold mist followed by about two minutes of dry gas, about five minutes of cold mist followed by about five minutes of dry gas, about ten minutes of cold mist followed by about ten minutes of dry gas, about 30 minutes of cold mist followed by about 30 minutes of dry- gas, or for a shorter or longer period (about ten minutes of cold mist followed by about two minutes of diy gas).
  • an equal period e.g., about 3 seconds of cold mist followed by about 3 seconds of dry gas, about 30 seconds of cold mist followed by about 30 seconds of dry gas, about one minute of cold mist followed by about one minute of dry gas, about two minutes of cold mist followed by about two minutes of dry gas, about five minutes of cold mist followed by about five minutes of dry gas, about ten
  • FIG. 1 illustrates an embodiment of a device having multiple ports for delivering a liquid inserted into the nasopharyngeal cavity according to the present invention for non-invasive cerebral and systemic cooling.
  • FIG. 2 illustrates an embodiment of a device having multiple ports for delivering a. liquid to the nasopharyngeal cavity according to the present invention for non-invasive cerebral and systemic cooling.
  • Fig. 2A an embodiment of a device having multiple ports tor separately transporting a gas and a liquid to the nasopharyngeal cavity and a switch for selectively connecting the liquid source to the device according to the present invention for noninvasive cerebral and systemic cooling
  • Fig. 3 illustrates an embodiment of a device having multiple ports for delivering a liquid to the nasopharyngeal cavity according to the present invention for non-invasive cerebral and systemic cooling.
  • Fig. 4 illustrates a cross-section of a nasal catheter having a plurality of lumens for separately transporting a liquid and a compressed gas according to the present invention.
  • Fig, 5 illustrates a cross-section of a nasal catheter having a plurality of ports for separately nebulizing a liquid and delivering a nebulized liquid spray to the nasal cavity according to the present invention.
  • FIG. 6A illustrates a cross-section of an alternative embodiment of nasal catheter having a plurality of lumens for separately transporting a liquid and a compressed gas according to the present invention.
  • Fig. 6B illustrates a cross-section of an alternative embodiment of a nasal catheter having a plurality of ports for nebulizing a liquid and delivering a nebulized liquid spray to the nasal cavity according to the present invention.
  • Fig. 7A illustrates a cross-section of an alternative embodiment of nasal catheter having a plurality of lumens for separately transporting a liquid and a compressed gas according to the present invention.
  • Fig. 7B illustrates a cross-section of an alternative embodiment of a nasal catheter having a plurality of ports for nebulizing a liquid and delivering a nebulized liquid spray to the nasal cavity according to the present invention.
  • Fig. 7C illustrates a cross-section of an alternative embodiment of a nasal catheter having a plurality of ports for nebulizing a liquid and delivering a nebulized liquid spray to the nasal cavity according to the present invention.
  • FIG. 7D illustrates a cross-section of an alternative embodiment of a nasal catheter having a plurality of ports for nebulizing a liquid and delivering a nebulized liquid spray to the nasal cavity according to the present invention
  • Fig 8 illustrates a cross-section of an alternative embodiment of nasal catheter having a plurality of lumens for separately transporting a liquid and a compressed gas according to the present invention.
  • Fig. 9 is a table of parameters and results for cerebral cooling trials performed wherein the compressed gas flow rate was maintained while the liquid flow rates were varied.
  • Fig, 10 is a graph of the nasal temperatures against liquid flow rate for the different compressed gas flow rates listed in Fig. 9.
  • Fig. 11 is a graph illustrating the gradient between cerebral and systemic cooling achieved using a method according to the present invention in a human.
  • Fig. 12 is a graph illustrating the gradient between cerebral and systemic cooling achieved using a method according to the present invention in a human.
  • Fig. 13 is a graph illustrating the gradient between cerebral and systemic cooling achieved using a method according to the present invention in a human.
  • Fig. 14 is a graph illustrating the gradient between cerebral and systemic cooling achieved using a method according to the present invention in a human.
  • Fig. 35 is a graph illustrating the gradient between cerebral and systemic cooling achieved using a method according to the present invention in a human.
  • Fig, 16 is a graph illustrating the gradient between cerebral and systemic cooling achieved using a method according to the present invention in a human.
  • Fig. 17 is a graph illustrating the gradient between cerebral and systemic cooling achieved using a method according to the present invention in a human.
  • Fig. 18 is a graph illustrating the gradient between mean cerebral and mean systemic cooling achieved using a method according to the present invention.
  • Fig. 19 is a graph illustrating the cooling rates achieved using a method according to the present invention for various delivery rates
  • Fig. 20 illustrates an embodiment of a device having a cooling helmet or cap with attached nasa! prongs according to the present invention for non-invasive cerebral and systemic cooling.
  • Fig. 21 illustrates an embodiment of a device having a mask with a nasal catheter inserted therethrough.
  • Fig. 22 A illustrates an embodiment of a device having a flexible balloon mounted on an elongate tubular member for insertion into the nasal cavity.
  • Fig, 22B illustrates the device of Fig. 22A inserted into a nasal cavity.
  • Fig. 23 A illustrates an alternative embodiment of a flexible balloon device for insertion into a nasal cavity.
  • Fig. 23B illustrates the device of Fig. 23A inserted into a nasal cavity.
  • Fig. 24 illustrates an embodiment of a device having a flexible balloon mounted on an elongate tubular member inserted down the esophagus
  • Fig. 25A illustrates a modified laryngeal, mask.
  • Fig. 25B illustrates an alternative embodiment of a modi ied laryngeal mask.
  • FIG. 25C illustrates use of the device of Fig. 25A.
  • Fig. 26 illustrates an embodiment of a flexible balloon device for insertion into the oral cavity.
  • Fig. 27 illustrates an embodiment of a device having a flexible balloon and a cold probe for insertion into the nasal cavity.
  • Fig. 28A illustrates an alternative embodiment of a device having a flexible balloon and a cold probe for insertion into the nasal cavity.
  • Fig. 28B illustrates the device of Fig. 28A inserted into a nasal cavity.
  • Fig. 29 illustrates an embodiment of a device having a flexible balloon mounted on a branched elongate tubular member for insertion into the nasal cavity.
  • Fig. 30 illustrates an alternative balloon shape.
  • Fig. 31 illustrates a fluid and gas delivery system.
  • Fig. 32A illustrates an embodiment of a device having an expandable member constructed according to the present invention for non-invasive cerebral and systemic cooling.
  • FIG. 32B illustrates an embodiment of a device having an esophageal suction tube constructed according to the present invention.
  • Fig, 33 illustrates an embodiment of a device having an esophageal suction tube and a gastric suction tube constructed according to the present invention
  • Fig. 34 illustrates an embodiment of a device having a nasal plug constructed according to the present invention.
  • Fig. 35 illustrates an alternative embodiment of a device having an expandable member constructed according to the present invention for non-invasive cerebral and systemic cooling.
  • Fig. 36 illustrates an embodiment of a device for delivering a liquid to the nasal and oral cavity according to the present invention.
  • Fig 37 is a table of experimental date from cerebral cooling trials performed wherein the cooling liquid used and the flow rate were varied.
  • Fig. 38 is a graph of is of brain temperatures against time for different runs listed in Fie. 37.
  • Fig. 39 illustrates an embodiment of a device having a spray nozzle constracied according to the present invention for non-invasive cerebral and systemic cooling via the nasal cavity.
  • Fig. 40 illustrates an embodiment of a delivery system constracied according to the present invention for deliver ⁇ ' of a liquid and gas for non-invasive cerebral and systemic cooling of the nasal cavity.
  • Fig. 41 illustrates an embodiment of a connecting tube for connecting the nasal catheter to the liquid deliver ⁇ ' system constracied according to the present invention.
  • Fig. 42 illustrates an embodiment of a connecting tube for connecting the nasal catheter to the liquid delivery system constructed according to the present invention.
  • Fig. 43 A illustrates an embodiment of a spray nozzle for use with the present invention.
  • Fig. 43B illustrates an embodiment of a spray nozzle for use with the present invention.
  • Fig. 43C illustrates an embodiment of a spray nozzle for use with the present invention.
  • Fig. 44 illustrates a mixing block for mixing the liquid and gas at the point of administration constracied according to the present invention
  • Fig. 45 illustrates a liquid delivery system for delivering the liquid to the point of administration constructed according to the present invention.
  • Fig. 46 illustrates an embodiment, of a device having an expandable member constmcted according to the present invention for non-invasive cerebral and systemic cooling via the nasal cavity.
  • Fig. 47 illustrates an embodiment of a device having proximal and distal expandable members constructed according to the present invention for non-invasive cerebral and systemic cooling via the nasal cavity,
  • Fig, 48 illustrates an embodiment of a device having proximal and distal expandable members constructed according to the present invention for non-invasive cerebral and systemic cooling via the nasal cavity.
  • Fig. 49 illustrates the use of a conductive gel with a device having proximal and distal expandable members constructed according to the present invention for non-invasive cerebral and systemic cooling via the nasal cavity.
  • Fig. 50 a flow chart illustrating a computerized method for controlling a cooling device to maintain a patient's temperature at a desired level.
  • Targeted cerebral cooling via cooling of the nasal and or oral cavities is possible because of the both direct heat transfer due to the proximity of the brain and hematogenous cooling through the carotids as they pass by the oropharynx and through the Circle of Willis, which lies millimeter away from the pharynx.
  • the direct cooling is obtained through evaporative heat loss in the nasal cavity.
  • the evaporative heat loss in the nasal cavity further results in convective cooling of the brain and eventually core body temperature
  • Evaporative heat loss in the nasal cavity can be achieved by spraying high volume air, or any other suitable substantially dry gas, into the patient's nasal cavity to evaporate the naturally occurring fluid in the nasal cavity.
  • Such forced evaporative cooling is minimally invasive and can be done without the need for airway protection in a non-medical or field setting.
  • delivering and evaporating a liquid coolant in the patient's nasal cavity achieves more substantial evaporative heat loss.
  • a liquid coolant can be delivered to the patient's nasal cavity in combination with the substantially dry gas such that the gas enhances the evaporation of the liquid coolant in the patient's nasal cavity resulting in cooling due to the evaporative heat loss of the liquid coolant in the nasal cavity.
  • Such a method will result in much more intense cooling, however, patients may need to be intubated and/or sedated before such "wet" cooling can be initiated.
  • Figs. 1-3 illustrate nasal catheter 10 with multiple delivery ports 12a-m for non-invasive cerebral and systemic cooling of the nasal cavity.
  • Nasal catheter i 0 is operably sized to extend through the patient's nasal cavity and into the nasal pharynx and has a plurality of lumens 14 and 16a-b extending between the proximal and distal ends of catheter 10 for separately delivering a liquid and a compressed gas.
  • Nasal catheter 10 also has rounded sealed tip 22 on the distal end, which seals the distal end of lumens 14 and 16a-b and provides a smooth surface to avoid damaging sensitive tissues.
  • Figs. 4-7 depict several possible designs for the lumens of nasal catheter 10.
  • Fig 4 shows catheter 10 with a large, circular central lumen 14 that may be used for transporting the compressed gas through catheter 10 while one or more smaller lumens 16a-b may be used for transporting the liquid through catheter 10.
  • Figs. 6-8 more complex, geometric extruded tubes are used to simplify the mixing process at each delivery port.
  • square central lumen 64 is provided for transporting the compressed gas through the catheter while the liquid may be transported in four outer sections 66a-d.
  • Figs. 7A-D depict an alternative embodiment where the gas lumen is a central geometric shape 74 and the four outer sections 76a-d form the channels for transporting the liquid.
  • additional lumens may be provided, for example, to permit inflation of an expandable member located on the distal end of the catheter or to permit suction of the non-evaporated liquid from the nasal cavity.
  • a plurality of ports 12a-m is located along the outer wail of catheter 10. These ports 12a-m are spaced apart longitudinally and axially along the outer walls of catheter 10 and are in fluid communication with lumens 14 and 16a-b transporting the liquid and compressed gas through catheter 10, For example, there may be about 10 - 40 delivery ports distributed around the circumference of the catheter and spaced apart, to cover the distance from about 3 cm to about 12 cm along the length of catheter 10. In use, when catheter 10 is placed in the nasal cavity of a patient, this distribution would provide full coverage of the nasal cavity.
  • each delivery port will be designed so that the liquid and gas flowing through the catheter lumens will be combined near the delivery port and the liquid will then be nebulized just prior to entering the nasal cavity.
  • each of ports 12a-m is formed by drilling mixing channel 18 in the outer wail of nasal catheter 10 connecting to central lumen 14 transporting the compressed gas.
  • liquid connecting tubes 20 are formed in the outer wall of catheter 10 to connect liquid lumens 16a-b with each of mixing channels 18 drilled between ports 12 a-b and compressed gas lumen 14, This provides for the ability to separately nebulize the liquid into a spray at each delivery port, Specifically, mixing channels 18 provide for gas flow outv/ard from central gas lumen 14 while liquid connecting tubes 20 permit addition of the liquid to the gas stream in channel 18, At this point, the gas is moving at a high velocity and the liquid experiences high shear forces, breaking the liquid stream into small droplets and creating a nebulized liquid for delivery via ports 12a-b.
  • the inner diameter of connecting tubes 20 and the shape and size of the ports 12a-b are important parameters and may be altered to vary the size of the liquid droplets and to optimize the spray pattern of delivery ports 12a ⁇ b.
  • a switch 17 may be provided to alternately connect and disconnect the source of liquid coolant to the liquid lumens 16a,b so that the same catheter 10 can be used to either deliver the gas alone to the patient's nasal cavity through the ports 12a-j, or alternatively, to deliver the gas combination with the nebulized liquid coolant to the patient's nasal cavity through ports 12a-j .
  • the switch 17 may be located in the proximal end of the catheter 10, as shown, or alternatively, the switch may be located at any point in the system between the source of liquid coolant and the liquid lumens 16a-b.
  • the catheter 10 can be used on a patient in a field or non-medical setting to deliver a substantially dry gas to the patient's nasal cavity to provide cooling due to the evaporative heat loss of naturally occurring fluids in the patient's nasal cavity
  • a dry gas source is connected to gas lumen 14 of catheter 10 and delivered at a high volume flow rate of between about 20 - lOOL min, alternatively between about 40- 1 OOL min, alternatively between about 50- 90L/mm, alternatively between about 60-SOL/nim to cause evaporative cooling in the nasal cavity which results in cerebral cooling of between about 0.3 to l°C hour
  • the dry gas source may be compressed or non-compressed.
  • Dry gases which can be used with this method, include air or any one of its components, oxygen, or a noble gas, such as Helium or Argon.
  • the dry gas may be an anesthetic agent, such as N 2 O 2 or Xe, which may have additional neuroprotective properties.
  • the substantially dry gas contains substantially no water vapor, and preferably has a relative humidity of less than about 20%, alternatively 10%, alternatively 5%, 2%, alternatively 1%, alternatively .5%, alternatively 0.1%.
  • the dry gas only cooling i.e. "dry” cooling
  • the liquid coolant is transported through liquid lumens 16a,b of catheter 10 and nebulized at the plurality of delivery ports 12a-j by gas delivered through gas lumen 14, as described above, prior to delivery onto the surface of the patients nasal cavity.
  • the dry gas is also used to enhance evaporation of the nebulized liquid coolant in the nasal cavity.
  • the patient may be intubated prior to initiating deliver ⁇ ' of the liquid coolant in order to prevent non- evaporated coolant from reaching the lungs in large quantities.
  • the patient may also be sedated to facilitate delivery of the liquid coolant.
  • the combination of the nebulized liquid coolant and dry gas i.e. "wet" cooling, provides significantly more cooling that gas only cooling due to the evaporative heat loss of the nebulized liquid coolant in the nasal cavity.
  • the cerebral temperature of the patient may be reduced from between about 0,1 to 5.0°C/ hour, alternatively from between about .5 to 4.0 C/ hour, alternatively from between about 1.0-3.5 °C/ hour.
  • This "wet” cooling is administered for between about 10 min to 9 hours to reduce the patient's cerebral temperature to between about i 8 to 36 °C. Once the desired brain cooling has been achieved, the "wet" cooling may be continued to maintain the patient's cerebral temperature at the desired temperature.
  • the cooling method may be switched back to the "dry" mode of cooling, i.e. gas only cooling, to maintain the brain at the reduced temperature for a prolonged period of time, For example, once the patient's cerebral temperature is reduced to between about 38 to 36 °C, the liquid coolant may be disengaged by using switch 17 to disconnect fluid communication between the liquid coolant source and liquid lumens 16a,b. Catheter 10 then reverts to delivering only dry gas through ports 12a-j.
  • the "dry" mode of cooling i.e. gas only cooling
  • the evaporative heat loss due to the dry gas evaporating naturally occurring fluids may be sufficient to maintain the reduced brain temperaiure for a period of between about 10 minutes to 240 hours, or longer if necessary.
  • the liquid coolant may be reengaged to initiate “wet” cooling again for a period of time sufficient to reduce the cerebral temperature back to the desired level. It may be that only a short period of "wet” cooling, such as between about 10-30 min, alternatively between about 5-60 min, is necessary to reduce the temperature back down to the desired level. Accordingly, in some embodiments, the "wet” cooling can be intermittently activated, for example by using switch 17 to reconnect the liquid coolant source to catheter 10, for a short period of time to maintain the patient's cerebral temperature at the desired reduced temperature for a prolonged period of time, using primarily "dry” cooling, which has the ad vantage of being much more cost effective. In addition, this method obviates the need to switch to another cooling device or method, such as an external cooling blanket or an intravascular cooling catheter, for maintaining the cooling for a prolonged period of time, as currently done.
  • another cooling device or method such as an external cooling blanket or an intravascular cooling catheter
  • a control unit 19 may be provided to allow an operator to activate switch 17 to turn on or off the liquid flow from the liquid coolant source.
  • the control unit 19 may also include software and a processor which allow if to be used in conjunction with one or more temperature sensors to automatically control the cooling therapy received by the patient based on the feedback regarding the temperature of the patient and a pre-determined desired temperature or temperature range set by the operator.
  • "dry" cooling only of the patient's nasal cavity is initiated as described above, to initially begin cerebral cooling, for example in a non-medical setting. Once the patient is brought into the hospital, a determination is made as to whether the patient needs more intense brain cooling.
  • the patient's temperature may be measured to make the determination regarding whether additional cooling is needed. Alternatively, other factors may be used, to assess whether additional cooling is needed.
  • the patient's temperature may be measured by measuring one or more of the patient's cerebral, esophageal, tympanic, body, bladder, blood or rectal temperature.
  • step 1004 "wet” cooling is initiated to provide additional cerebral cooling.
  • the “wet” cooling may be continued for between about 10 minutes to 9 hours.
  • an operator inputs the target temperature into the control system.
  • the operator may set a target temperature range for either the core or cerebral temperature,
  • the target temperature range could be within a range of about 30 to 37°C for the core temperature, such as a range of between about 30-32 °C, alternatively a range of between about 32-34 °C, alternativeiativeiy a range of between about 34-36 °C, alternatively a range of between about 30-34 °C, alternateiativeiy a range of between about 32-36 °C, alternatively a range of between about 34-37 °C, alternatively a range of between about 32-37 0 C.
  • the control unit 19 may be connected to a means for measuring the temperature, such as a thermometer, sensor or temperature sensors known in the art, such that the control unit automatically controls measuring the temperature.
  • the control unit 19 may give a warning or indication that the temperature needs to be measured.
  • the operator compares the measured temperature to the target temperature range.
  • the "wet" cooling is continued until the temperature is again measured and is found to be within the target temperature range.
  • the switch 17 is activated to disconnect communication with the liquid source and at step 1016, cooling reverts back to "dry” cooling using only the substantially dr gas.
  • the patient's temperature is measured.
  • the measured temperature is analyzed against the target range set by the operator in step 1006. if the temperature is still within the target range, at step 1026, the "dry" cooling is continued until the next interval for measuring the patient's temperature.
  • step 1022 If the patient's temperature has risen above the target temperature, at step 1022, switch 17 is activated to reconnect the liquid source to the catheter 10 and at step 1024, "wet” cooling is reinitiated to reduce the patient's temperature back into the target temperature range. The “wet” cooling is continued until the next interval for measuring the patient's temperature at step 1008. if the patient's temperature is back within the target range at step 1010, the “wet” cooling will be discontinued at step 1014 and “dry” cooling only will be continued at step 1016. If the patient's temperature has not been lowered back into the target range at step 1010, the "wet” cooling will be continued until the next interval for measuring the patient's temperature. The patient's temperature can be maintained within the target range in this manner for a period of to about 10 days, or longer if necessary,
  • other ranges or limits for the patient's temperature could be used with a different set of instructions for controlling the amount of and type of cooling delivered.
  • the control system could be programmed such that the operator sets a target temperature for the cerebral temperature between 18-36°C, alternatively 19-36 °C, alternatively 20-36 °C, alternatively 23-36°C, alternatively 25- 36°C, alternatively 27-36°C, alternatively 30-36°C, alternatively 34-36°C, alternatively 32-36°C, alternatively 32-34°C, depending upon the patient's condition and includes instructions to maintain the patient's cerebral temperature within ⁇ 0.5°C of the target temperature, alternatively ⁇ 0.1°C of the target temperature, ⁇ 1°C of the target temperature, ⁇ 1 ,5°C of the target temperature, ⁇ 2°C of the target temperature, ⁇ 3°C of the target temperature.
  • the target temperature could be a minimum
  • Figs. 6A-B and 7A-D depict alternative configurations for the liquid and gas channels within the nasal catheter and delivery ports on the outer walls of the catheter that may provide for easier mixing of the liquid and compressed gas at the delivery port.
  • the nasal catheter is formed of a length of extruded tubing with interior side walls 63a-d creating a central square lumen 64 in which the compressed gas may be transported and four separate outer channels 66a-d in which the liquid may be transported.
  • mixing channel 68 is drilled through the outer wall of the catheter at one of the comers where two of side walls 63a-b of the central lumen 64 connect with the outer wall of the catheter, openings 60a and 60b are created in each of the adjacent interior channels 66a-b through which liquid can enter the gas stream flowing through mixing channel 68.
  • This design simplifies the construction of the device by eliminating the need for a separate connecting tube to connect the liquid lumens with the mixing channel.
  • the size of mixing channels 60a-b may be altered to provide for a desired liquid flow rate by adjusting the diameter of mixing channel 68. Figs.
  • FIG. 7A-D depict an alternative embodiment of a nasal catheter with a shaped central lumen 74 for transporting the compressed gas surrounded by four outer channels 76a-d for transporting the liquid.
  • Delivery ports 72 are created by making skyved cuts 73 in the outer wall of the catheter, which creates aperture 77 from the gas lumen 74 and openings 75a-b into the outer channels 76a-d transporting the liquid from which the liquid can enter into the gas stream.
  • the skyved cuts may be rectangular 73, circular 78, or V-shaped 79, and may be of varying sizes to affect both the velocity of the nebulized liquid, flow rate, and size of the spray particles.
  • central lumen 84 may be used to transport, the liquid, wkile four outer channels 86a-d are used to transport the compressed gas.
  • Delivery port 82 is created by making a skyved cut in the outer wall of the catheter at the junction of the central lumen 84 and two adjacent liquid channels 86a-d. The skyved cut provides an aperture through which, the compressed gas from outer gas channels 86a-d can escape and also creates central slit 85 in fluid communication with central lumen 84 for introducing the liquid from central lumen 84 into the gas stream.
  • this may be advantageous for providing a wider dispersion of flo from each delivery port 82.
  • the liquids used with this catheter include liquids having a boiling point between about 38 and about 300 °C, alternatively a boiling point of between about 38 and about 200 °C, alternatively a boiling point of between about 60 and about 150°C, alternatively a boiling point of between about 70 and about 125°C, alternatively a boiling point of between about 75 and about 1 10°C, alternatively a boiling point of between about 60 and about 70°C.
  • Compounds having suitable characteristics for use herein include hydrocarbons, fluorocarbons, peril uorocarbons, and perfluorohydrocarbons.
  • Saline is another example of a substance having suitable characteristics for use herein. As used in this specification, the terms "fluorocarbon,” “peril uorocarbon,” and
  • perfluorohydrocarbon are synonymous, in addition to containing carbon and fluorine, these compounds may also contain other atoms, in one embodiment, the compounds could contain a beteroatom, such as nitrogen, oxygen, sulfur, or a halogen, such as bromine or chlorine. These compounds may be linear, branched, or cyclic, saturated or unsaturated, or any combination thereof.
  • Exemplary perfluorocarbons include perfluoropropane. perfluorobutane, perfluoropentane, 2-meth.yl-perfluoropentane, perfhiorohexane, perfluoroheptane, and perfluoroociane.
  • the liquids delivered through the catheter may also comprise a humidifier
  • the humidifier may be delivered separately through the catheter or using an alternative delivery device, When used in conjunction with the cooling liquid, the humidifier would have to be cooled or else it would counteract the cooling effect of the other liquid. Where the humidifier was used independently for humidification, it could also be warmed.
  • the humidifiers may be delivered througli the same ports in the catheter as the cooling liquid. Alternatively, a different lumen and/or port in the catheter may be used to deliver the humidifier.
  • the purpose of the humidification is to prevent the sensation of dryness, the crusting and trauma that could result from the dryness, the nasal congestion and mucous production that could result from dryness imparted by the high gas flow rates or from the evaporation of the liquid (e.g., PFC).
  • the congestion and mucous production reduce the effectiveness of the cooling by limiting the cavity in which the evaporation occurs and by directly blocking holes in the catheter. This phenomenon may account tor rapid initial cooling rates observed, followed by slower cooling rates beyond the first 20 to 30 minutes.
  • the humidifier may be, but is not limited to isotonic saline, or water. Where water is used as the humidifier, the quantity needed to be added for full saturation is about 41 microgram s/L of gas.
  • Alternative nasal inhalers such as but not limited to, ephedrine, pseudoephedrine (e.g., Afrin), antihistamines, ipratropium (e.g., Atrovent), and anticholinergics, may also be used to saturate the air in the nasal cavity.
  • the gases used with the catheter include any gas capable of evaporating the liquid,
  • the gas can include, but is not limited to, nitrogen, air, oxygen, argon, or mixtures thereof.
  • this catheter In use, as seen in Fig. 1 , this catheter is intended to be placed through the patient's nostrils and extend through the nances of the nose to the nasopharyngeal region of the nasal cavity.
  • the length of catheter 10. which extends to the nasal pharyngeal region of the nasal cavity and multiple ports 12a-m located longitudinally and axially along the outer wall of the catheter enable catheter 10 to disperse the liquid spray perpendicular to the longitudinal axis of catheter 10 and over the entire nasal cavity region. This is in contrast to simply directing the spray through a single spray nozzle at a catheter tip, which would have the spray limited to a particular area along the longitudinal axis of catheter. This distinction is critical in that dispersing the spray over a larger region permits greater cooling though evaporative heat loss.
  • the ability to nebulize the liquid at each delivery port ensures that the distribution of varying sizes of liquid particles will be uniform throughout the nasal cavity. Specifically, when a liquid is nebulized, a spray with liquid particles of various sizes is created. If the liquid was nebulized at the proximal end of the nasal catheter or outside of the catheter and then transported as a nebulized liquid spray through the catheter lumen to the multiple delivery ports, the smaller liquid particles would flow through the proximal delivery ports while the larger liquid particles would be carried to the distal end of the tube before being delivered to the nasal cavity via one of the delivery ports near the distal end of the nasal catheter. This would result in an uneven distribution of the liquid particles within the nasal cavity.
  • the size distribution of liquid particles distributed at any given point in the nasal cavity is uniform. This is critical because an even distribution of the varying sized liquid particles provides for better evaporation of the liquid spray, which results in better cooling through evaporative heat loss and is more tolerable to the patient. Furthermore, since the liquid begins to evaporate immediately upon contact with the gas, mixing at the point of use in the patient will ensure efficient use of all available cooling.
  • the liquid flow rate is also a critical factor for cerebral cooling.
  • Fig. 30 depicts the amount of nasal cooling per different liquid flow rates.
  • the gradient between the cerebral and systemic cooling that forms over time is desirable in order to minimize damage to other organs asid hypothermia during the cerebral cooling, in order to create a gradient between the cerebral and systemic temperature, the cerebral cooling must be induced rapidly, for example at a rate of at least about 1 °C in hour, alternatively at least about 1.5°C in hour, alternatively at least about 2°C in hour, alternatively at least about 3°C in hour, alternatively at least about 4°C in hour, alternatively at least about 5°C in hour between the cerebral temperature and the systemic temperature.
  • This sudden initial exposure to cold induces a vasoconstriction response in the carotid arteries causing the carotid arteries to constrict, which helps isolate the cerebral vasculature and prevent warmer blood from the heart traveling to the brain and the cooler blood in the brain from traveling to and thereby cooling the rest of the body.
  • This initial vasoconstriction response thus further aids the cooling process by preventing warmer blood from traveling to the head .
  • the initial cooling lowers the metabolic demand of the head, thus the carotid artery can further constrict and further isolate the head.
  • the spray may be delivered at. a lower flow rate.
  • the lower flow rate may result in a gradient between the cerebral and systemic temperature of at least about 0.1 °C, alternatively at least about 0.2°C, alternatively at least about 0.3°C, alternatively at least about 0.4°C, alternatively at least about 0,5°C, alternatively at least about 0.6°C, alternatively at least about 1.0°C, alternatively at least about 1.5°C, alternatively at least about 2,0°C, alternatively at least about 2.5°C, alternatively at least about 3.0°C, alternatively at least about 3.5°C, alternatively at least about 4.0°C ? alternatively at least about 4,5°C, alternatively at least about 5,0°C.
  • the ratio for the liquid delivery rate: gas delivery rate to optimize the evaporation and maintain a constant rate of evaporation preferably ranges from 1 :25mL - 1 :5000mL, more preferably from 1 :500mL - 1 :2000raL, more preferably from 1 :700mL - 1 : 1500mL. Figs.
  • FIG. 9- 10 depict the varying cooling in an artificial nasal cavity at three different gas flow rates (40 L/min, 30L/min, and 50 L/min) as the liquid flow rate is varied.
  • the goal is to have 300% evaporation (i.e., "spray"). It is desirable to have the maximum amount of cooling with the least amount of liquid used. Therefore, the gas flow rate should be at least about 30 L/min, alternatively at least about 40 L/min, alternatively at least about 50 L/min.
  • the liquid flow rate should be at least about 40 mL/min, alternatively at least about 50 mL/min, alternatively at least about 60 mL/min, alternatively at least about 70 mL min, alternatively at least about 80 mL/min, alternatively at least about 90 mL/min.
  • the flow rate of the gas and liquid can be altered during the process according to the amount of cooling achieved.
  • Feedback can be provided in the form of nose temperature, body temperature, brain temperature, rectal temperature, etc. For example, an alarm could be triggered when the body temperature falls below 35°C and delivery of the fluids and gas could he stopped. Additionally, or in the alternative, feedback in the form of the brain temperature could be provided such that the rate of delivery of the fluids and gases increases if the cooling rate of the brain is less than about 5 °C in one hour, alternatively less than about 4 °C in one hour, alternatively less than about 3 °C in one hour, alternatively less than about 2 °C in one hour, alternatively less than about 1 °C in one hour.
  • T2 is the temperature to which the liquid is warmed
  • Equation 2 Q ⁇ h * m
  • the maximum whole body cooling that could occur from a 2 liter dose is approximately 1.7°C This should result in a body temperature no lower than 35°C, which should not cause any cold related complications.
  • the sensitivity i.e., the resultant temperature change experienced by the patient, will depend on the size of the patient.
  • the resultant temperature change is ⁇ ⁇ OOkcal / (0.83cai/g°c * 100kg) - 0.83 °C.
  • the head cooling calculation assumes that absolutely no heat will be added to the head from the body. This is, however, a poor assumption.
  • the cerebral blood flow s on the order of 1 L per minute, and assuming that this blood is cooled by only 2 degrees while in the head, the calculation becomes as follows:
  • the cooling in the head is reduced by at least half of the previously calculated value to 12°C, for a minimum possible 25°C head temperature
  • the nasal catheter of the present invention was inserted through the nose into the nasal cavity, Temperature was measured at baseline (3 times over 10 minutes) and at every minute or continuously at the ventricle or epidural space, where available, and bladder or rectum during the procedure.
  • a suction catheter was positioned in the patient's mouth to prevent pharyngeal liquid from entering the esophagus and a nasogastric (NG) tube was placed in the patient's stomach to suction any liquid PFC or PFC vapor. NG suction was continuous.
  • Nasal cooling was administered via a nasal catheter with one oxygen/PFC mixer and fan spray nozzle per naris.
  • Nasal prongs were positioned in the narices and secured to the nose by tape.
  • the PFC (e.g., peril uorohexane) was delivered at a rate of about 15 mL/min , alternatively at about 25 mL/min, alternatively at about 35 raL/min, alternatively at about 45 mL/m n, alternatively at about 50 mL/min, alternatively at about 55 mL/min, alternatively at about 65 mL/min, alternatively at about 75 mL/min, alternatively at about 80 mL/min, alternatively at about 85 mL/min, alternatively at about 95 mL/min, alternatively at about 100 mL/min, depending on the patient.
  • peril uorohexane e.g., peril uorohexane
  • the liquid flow rate was sometimes started at a lower flow rate (e.g., about 15 mL/min or about 25 mL/min) and increased to a faster flow rate (e.g., about 45 mL/min, about 50 mL/min, or about 100 mL/min).
  • the liquid flow rate was started at a faster flow rate (e.g., about 50 mL/min) and gradually reduced to a slower flow rate (e.g., about 25 mL/min).
  • a total of amount of about 1.0 L of PFC was delivered, alternatively about 1.5 L, alternatively about 2.0 L, depending on the patient.
  • the delivery period was approximately 20 minutes, alternatively approximately 25 minutes, alternatively approximately 30 minutes, alternatively approximately 35 minutes, alternatively approximately 40 minutes, alternatively approximately 45 minutes.
  • oxygen is delivered at about 40 L/min and PFC is delivered at about 80 mL/min throughout the delivery period. A total of about 2 L of PFC is delivered. The delivery period is approximately 20 to 25 minutes.
  • Figs. 1 1-17 illustrate the gradient between the cerebral and systemic temperatures achieved using the methods described above. The rectangles at the bottom of the graphs indicate the delivery periods for that particular therapy.
  • Fig. 18 illustrates the mean cerebral and systemic cooling achieved from the experiments illustrated in Figs. 1 1 -17.
  • Fig. 19 illustrates the cooling temperatures achieved using various delivery rates, As apparent from the figures, selective cooling of the brain is achieved and maintained over time, even after delivery of the cooling agents has stopped.
  • a gradient between cerebral and systemic temperature of at least about 0.5 °C can be achieved, alternatively about 1.0 °C can be achieved, alternatively about 1.5 °C can be achieved, alternatively about 2.0 °C can be achieved, alternatively about. 2.5 °C can be achieved.
  • the catheter of the present invention can also be used in combination with other cooling or heating devices.
  • the catheter may be used in combination with a helmet or cooling cap for synergistic cooling as seen in, for example, U.S. Patent No. 6,962,600, which is hereby expressly incorporated by reference in its entirety.
  • a cooling system 100 comprising a cooling helmet or cap 102 with the nasal catheters or prongs 1 10 of the present invention attached directly to the cooling helmet or cap.
  • the nasal catheters or prongs may not be attached to the cooling cap or helmet, and still be used in conjunction with the cooling cap or helmet for synergistic cooling (not shown).
  • the cooling system 100 includes a recirculating liquid refrigerant container 104 with an input line 106 and an output line 108 running from the container 104 to the cooling helmet or cap 102.
  • the helmet may only have an input line where cooling is accomplished through evaporation of the liquid refrigerant within the walls of the cooling helmet or cap (not shown).
  • the nasal catheters may be used in combination with a warming blanket to enhance the gradient between the cerebral temperature and the systemic temperature where systemic cooling is inadequate to bring down the brain temperature.
  • a heat pump could be used in conjunction with a cooling helmet or cap and a warming blanket. The heat pump could take heat from the liquid being circulated to the cooling helmet or cap and pump the heat into the warming blanket. The heat pump could use a refrigerant or thermoelectric cycle.
  • a mask can be used in conjunction with the catheter (single or multi-lumen) to increase the amount of air/oxygen/gas delivered to the nasal cavity. This would resul in an increase in the rate of liquid evaporation, and therefore the rate of cooling, without increasing the intranasal pressure.
  • mask 280 such as a continuous positive airway pressure (CPAP) nasal mask, can have catheter 282 fitted therethrough. The positive pressure is given through mask 280.
  • CPAP continuous positive airway pressure
  • the pressures given through the mask may be about 0 to about 200 cm H 2 0, alternatively about 0 to about 150 cm H G, alternatively about 0 to about 100 cm ⁇ 2 ⁇ , alternatively about 0 to about 75 cm H?0, alternatively about 0 to about 60 cm i3 ⁇ 40, alternatively about 0 to about 50 cm !3 ⁇ 40, alternatively about 0 to about 40 cm 3 ⁇ 4Q.
  • Valve 284, preferably a one-way valve, at the side of mask 280 can open at a given pressure, thereby releasing excess gas into the atmosphere.
  • Valve 284 acts as a safeguard against high intranasal pressures that could conceivably lead to gas entrapment in the tissue or entry into the venous vasculature, resulting in a pulmonary embolism.
  • Valve 284 may open when the pressure inside the mask reaches about 55 cm 3 ⁇ 40, alternatively about 60 cm 3 ⁇ 4Q, alternatively about 65 cm H 2 0.
  • mask 280 is placed over the nose and nasal catheter 282 is inserted into the nasal cavity, as described previously. Air and gas are expired through the mouth, as in standard CPAP treatment.
  • the catheters of the present invention can also be used as drag delivery catheters for delivery of nebulized drugs to the nasal cavity, ii is further contemplated that these drugs may be delivered unaccompanied or may be delivered in addition to a cooling agent to facilitate cerebral cooling.
  • nebulized drugs may be delivered unaccompanied or may be delivered in addition to a cooling agent to facilitate cerebral cooling.
  • the drug delivery catheter may include, but is not limited to, at least 20 delivery ports, alternatively at least 30 delivery ports, alternatively at least 40 delivery ports, alternatively at least 50 delivery ports, atiematively at least 60 delivery ports.
  • Use of such a drag delivery catheter with nebulizing deliver ⁇ ' ports may- provide more accurate dosing than existing nasal delivery systems, which suffer from problems of liquid dripping down the patient's throat.
  • the drag could be provided in a liquid suspension or a mixture.
  • the liquid suspension could utilize various liquid carriers, depending on the drug.
  • Liquid carriers include, but are not limited to, water, saline, PFC, and combinations thereof.
  • Use of saline as a carrier has an advantage in that many drugs are already sold with saline as the carrier. Additionally, there are no suspension problems.
  • Use of a PFC as a carrier has an advantage in that, because the PFC would evaporate, the drag would not be diluted.
  • Drugs that may be delivered using an intranasal deliver ⁇ 7 catheter include, but are not limited to, neuroprotective agents and malignant hyperthermia, insulin, ⁇ -h!ockers. ⁇ -agonists, antihistamines, contraceptives, anesthetics, painkillers, antibiotics, steroids, aspirin, sumatriptan, Viagra, nitroglycerin, hormones, neurodrugs, anti-convulsants, prozac, anti-epileptics, analgesics, NMD A antagonists, narcan, noxone, naltrexone, anxiolytics, and muscle relaxants,
  • specialized nasal catheter 800 is described for the application of a nebulized liquid, preferably a perfluorocarbon (PFC), for cerebral and systemic cooling.
  • PFC perfluorocarbon
  • This embodiment comprises a multi-lumen elongate member 802 with a length operable to extend a patient's esophagus to be inserted through the nose, and into the esophagus 804,
  • balloon 806 is located near the distal end. This may be used to occlude the esophagus 804.
  • Catheter 800 includes at least a first, second, and third lumen.
  • First lumen 810 of the elongate member may then be used for suctioning vapor and or liquid from the stomach.
  • Second lumen 812 may be exposed proximal to balloon through port 814, to allow suctioning vapor or liquid which enters the upper esophagus.
  • Third lumen 816 which is in fluid communication with multiple ports along catheter 800, may be used as a spray lumen.
  • Fourth lumen is a balloon inflation lumen and is in fluid communication with a chamber defined by balloon 806. In operation, catheter 800 is placed and balloon 806 inflated to occlude the respective passage, i.e., the esophagus. Gastric suction through lumen 810 can be applied per clinical practice.
  • Air or oxygen
  • a PFC liquid is added to spray lumen 816; this will produce a fog of droplets in the nasal cavity.
  • Much of the PFC liquid will impact and coalesce on the walls of the nasal cavity and associated passages. This will then drain down to the throat, the majority of which will enter the esophagus where it can be suctioned through the proximal suction port and reused.
  • Some of the PFC may enter the lungs either directly as liquid or as droplets carried on the inhaled breath
  • plug or balloon 822 may be located at the entrance to the nasal cavity to prevent any retrograde flow out of the nose.
  • the elongate member may be bifurcated outside the nose, with an additional prong and balloon (not shown) for the other nostril.
  • catheter 830 may be bifurcated near the proximal end into two tubular members 832 and 834 for delivery of liquid and/or oxygen to the nasal and oral cavities, respectively.
  • a second elongate member could be s!ideably inserted into tubular member 834 for delivering liquid and/or oxygen to the oral cavity.
  • the elongate tubular member inserted into the oral cavity may be independent of the nasal catheter (not shown).
  • the advantages of this invention include: relative ease of placement: available port provides same function as nasogastric tube; similarity to standard nasogastric tubes in design and use; ease of breathing, speaking, etc., through mouth for the patient; liquid flow rate is not dependant on ventilation and can be set by clinician; high turnover flow through cooling enabled; utilization of well perfused anatomical features; perfluorocarbon is well tolerated in lungs; peril uorocarbon in the stomach is also tolerated, and can be easily suctioned with the gastric portion of the catheter.
  • compositions of the invention include liquids having a boiling point between about 38 and about 300 '3 C, alternatively a boiling point of between about 38 and about 200 °C ? alternatively a boiling point of between about 60 and about 150°C, alternatively a boiling point of between about 70 and about 125°C, alternatively a boiling point of between about 75 and about 1 10°C, alternatively a boiling point of between about 60 and about 70"C.
  • Compounds having suitable characteristics for use herein include hydrocarbons, fluorocarbons, perfluorocarbons, and perfluorohydrocarbons. Saline is another example of a substance having suitable characteristics for use herein. As used in this specification, the terms "fluorocarbon,” “perfluorocarbon,” and
  • perfiuorohydrocarbon are synonymous. In addition to containing carbon and fluorine, these compounds may also contain other atoms. In one embodiment, the compounds could contain a heteroatom, such as nitrogen, oxygen, or sulfur, or a halogen, such as bromine or chlorine. These compounds may be linear, branched, or cyclic, saturated or unsaturated, or any combination thereof.
  • the compounds are highly fluorinated compounds, which are compounds containing at least three fluorine atoms.
  • Tiiese highly fluorinated compounds may also contain other atoms besides carbon and fluorine. These other atoms include, but are not limited to, hydrogen; heteroatoms such as oxygen, nitrogen, and sulfur; and halogens such as bromine or chlorine.
  • the number of the atoms that are not carbon or fluorine comprise a minority of the total number of atoms in the compound.
  • These highly fluorinated compounds may be linear, branched, or cyclic, saturated or unsaturated, or any combination thereof Examples of these compounds include, but are not limited to, (b.p, 43°C),
  • the compounds are hydrofluorocarbons, which are compounds where the number of hydrogen atoms exceeds the number of fluorine atoms.
  • These hydrotluorocarbons may also contain other atoms besides hydrogen, carbon, and fluorine. These other atoms include, but are not limited to, heteroatoms such as oxygen, nitrogen, and sulfur and halogens such as chlorine and bromine.
  • hydrotluorocarbons include, but are not limited to,
  • hydrochlorofluorocarbons more specifically, hydrocMorofiuoralkanes.
  • the number of the atoms other than carbon and fluorine comprise a minority of the total number of atoms in the compound.
  • These hydrofluorocarbons may ⁇ be linear, branched, or cyclic, saturated or unsaturated, or any combination thereof.
  • a mixture of two or more highly fluorinated compounds, hydrotluorocarbons, light fluorocarbons, hydrocarbons, fiuorocarbons, peril uorocarbons, perfluorobydrocarbons, or any of the above-mentioned compounds may also be used.
  • the mixture may contain any of the previously mentioned compounds in different phases (e.g., one gas, one liquid),
  • the mixture has a boiling point above 37 °C, eve though any individual component of the mixture may have a boiling point below 37 °C.
  • Light fluorocarbons are fluorocarbons that have a boiling point below 37 °C. These light fluorocarbons may also contain other atoms besides carbon, and fluorine. These other atoms include, but are not limited to, hydrogen; heteroatoms such as oxygen, nitrogen, and sulfur; and halogens such as chlorine and bromine.
  • light fluorocarbons include, but are not limited to perfiuorobutane and perfluoropeniane, In one embodiment, the number of the atoms other tha carbon and fluorine comprise a minority of the total number of atoms in the compound, These light fluorocarbons may be linear, branched, or cyclic, saturated or unsaturated, or any combination thereof.
  • a liquid having a boiling point of between about 38 and about 300 °C, alternatively a boiling point, of between about 38 and about 200 °C, alternatively a boiling point of between about 38 and about 150 °C is selected.
  • the liquid is nebulized to form a mist.
  • the droplets preferably range in size from 0.1 - ⁇ 300 microns, more preferably 1 - 5 microns, more preferably 2 - 4 microns.
  • the mist is optionally cooled below body temperature and delivered to the airway of a patient so that the patient inhales the mist.
  • Inhalation of the mist causes systemic cooling by heat transfer from the lungs to the cooler mist and/or by evaporative heat loss as the mist evaporates. Trie administration of the liquid is continued until the systemic temperature is reduced to 35 °C or below, more preferably to 34 °C or below, more preferably to 33 °C or below.
  • the rate of cooling can be adjusted by varying the temperature of the inhalate, the concentration of the responsible compound or compound mixture, the rate of delivery, the particle size, and the percentage of each compound in the mixture,
  • Nitric oxide or adrenergic agents such as adrenaline (epinephrine) or albuterol, may be added in minute doses to the compositions described in an of the previously described embodiments.
  • the NO or other agent is inhaled and acts as a potent nasal vasodilator, which improves the rate of action of the cooling mist and counteracts nasal vasoconstriction caused by administering cold substances to the nasal cavity.
  • the NO may be included in an amount of about 2 to about 80 parts per million, in other cases in an amount of about 3 to about 20 parts per million, in other cases in an amount of about 4 to about 10 parts per million, in other cases in an amount of about 5 to about 8 parts per million, in other cases in an amount of about 5 parts per million.
  • administering preferably a cold dry gas such as dry air or dry heliox, e.g., a mixture of helium and oxygen.
  • a cold dry gas such as dry air or dry heliox, e.g., a mixture of helium and oxygen.
  • the gaseous phase in the nasal cavity may become saturated with gaseous PFC, thereby slowing the rate of evaporative heat loss.
  • cycling it is recommended that the cycles occur tor about 3 seconds or more, in other cases for about 30 seconds or more, in other cases for about one minute or more, in other cases for about two minutes or more, in other cases for about five minutes or more, in other cases for about ten minutes or more, in other eases for about 30 minutes or more.
  • the intervening cycle of dry gas may last for an equal period (e.g., about 3 seconds of cold mist followed by about 3 seconds of dry- gas, about 30 seconds of cold mist followed by about 30 seconds of dry gas, about one minute of cold mist followed by about one minute of dry gas, about two minutes of cold mist followed by about two minutes of dry gas, about five minutes of cold mist followed by about five minutes of dry gas, about ten minutes of cold mist followed by about ten minutes of dry gas, about 30 minutes of cold mist followed by about 30 minutes of dry- gas, or for a shorter or longer period (about ten minutes of cold mist followed by about two minutes of dry gas),
  • an equal period e.g., about 3 seconds of cold mist followed by about 3 seconds of dry- gas, about 30 seconds of cold mist followed by about 30 seconds of dry gas, about one minute of cold mist followed by about one minute of dry gas, about two minutes of cold mist followed by about two minutes of dry gas, about five minutes of cold mist followed by about five minutes of dry gas, about
  • a liquid having a boiling point between about 38 ami about 300 °C is selected.
  • the liquid is nebulized to form a mist.
  • the droplets preferably range in size from 1 - 5 microns.
  • the mist is delivered to the nasal and or oral cavities of a patient so that the patient, of the mist causes cerebral cooling by heat transfer to the cooler mist and/or by evaporative heat loss, in addition indirect hematogenous cooling occurs through the carotids as they pass by the oropharynx and through the Circle of Willis which lies millimeters away from the pharynx.
  • the administration of the liquid is continued until the cerebral temperature is reduced to 35 °C or below, more preferably to 34 °C or below, more preferably to 33 C C or below.
  • the administration of the liquid may be continued to provide for systemic cooling as well as cerebral cooling, in certain methods, the liquid may be cooled to below body temperature before delivery.
  • the mist droplets may range in size from 1 - 5 microns.
  • the table in Fig. 37 lists the parameters and results for cerebral cooling trials where the perfluorocarbon mixture used and the flow rate at which it was provided were varied.
  • the column entitled “PFC” lists the perfluorocarbon used and the column entitled “PFC flow ml/rnin” lists the flow rate at which the PFC was adminisiered.
  • the gas flow rate is listed in the column entitled “0 2 Flow Urn in;” the greater the gas flow rate, the greater the cooling.
  • the gas joined the liquid in a box and generated a spray. The spray was then delivered to the nasal cavity.
  • Possible nasal trauma limited the speed of delivery; for example, nasal bleeding may be rate limiting.
  • the ratio between the gas and the liquid was varied (e.g., 1 : 1 , 3 :2, 1 :3) with varying effect on cooling rates.
  • the column entitled "BIAS flow” is CPAP (continuous positive ainvay pressure) air under several atmospheres of pressure to enhance spray entry during inspiration. Cooling was measured in Head-F (frontal lobe of the brain), Head V (ventricle of the brain), Head-S (superficial, cortical, and posterior portions of the brain), Vase (vascular column), and Rectal (rectal column), Systemic column was measured in the vascular column. From the measurements it appears that Head F cools first and the fastest.
  • the cold diffuses back to the ventricle and then to surface.
  • a gradient is created within the brain and between brain and blood, such that brain cooling is more marked early on (20-30 degrees in one hour) than blood (10 degrees in one hour), systemic cooling, or rectal cooling. This gradient eventually disappears.
  • Fig. 38 shows a plot of brain temperatures against time for different runs listed in Fig 37.
  • Table 1 shows additional experimental data wherein the cooling liquid and the flow rate were varied.
  • Fig. 39 illustrates nasal catheter 910 for non-invasive cerebral and systemic cooling of the nasal cavity
  • the nasal catheter has a rounded sealed tip 912 on the distal end, which provides a smooih surface to avoid damaging sensitive tissues.
  • Tip 912 may be sealed by selective melting of the distal end of the catheter, in use, catheter 910 is intended to be placed in the nares of the nose, so that a spray outlet (not shown) may be directed at the desired structures of the nasal cavi ty, specifically the nasal conchae.
  • the spray nozzle on the distal end of nasal catheter 10 is designed so as to cause the spray to spread in a pattern which will allow the gas/liquid mixture to contact as much of the desired tissues as possible, By doing this, any mechanical trauma due to a concentrated high velocity jet should be minimized.
  • Figs. 43 A-C depict several possible designs for the spray nozzle for creating varying spread spray patterns.
  • Fig, 43 A shows nasal catheter 910 wherein the spray nozzle has been formed by drilling multiple holes 940 along the outer wall of nasal catheter 910, in use, this pattern produces will produce a broad, flat spray perpendicular to the axis of the catheter.
  • This pattern may be further customized by drilling corresponding holes in the opposite si de of the catheter wall (not show), or by changing the size, location and number of holes drilled in the catheter outer wall in addition, it may also be possible to include a hole in the catheter tip 12 (hole not shown), to produce some additional flow in the axial direction,
  • Fig, 43B show r s nasal catheter 910, wherein the spray nozzle has been formed by cutting a rectangular slit 942 in tip 912 of catheter 910,
  • this pattern produces a fan shaped spray centered along the axial direction of the catheter,
  • the width and length of slit 942 will dictate the character of the spray.
  • the pattern may, therefore be customized by varying the width and length of slit 942.
  • the symmetry of the spray may be altered by cutting slit 942 to extend farther down one side catheter 910 than the other.
  • the spray pattern may be altered by adding one or more additional slits of varying widths and lengths (not shown),
  • Fig. 43C shows a nasal catheter 910, wherein the spray nozzle has been formed by making an angled straight cut 944 or a curved cut (not shown) in the side of catheter 910, including a portion of catheter tip 912. in use, this skived cut produces a wide 'fan' shaped spra which covers a broad angle from the perpendicular to the axial directions of catheter 910.
  • any of the patterns depicted in Figs. 43A-C could also be combined to further disperse the spray. For example, holes could be cut along the length of a skived tip catheter to cover a wider area, or a slit could be cut in the tip of a the drilled hole catheter to enhance flow in the axial direction.
  • Fig. 40 shows a dual-lumen mixing catheter 914 connected to two nasal catheters 910 for separately delivering a liquid and a gas to the proximal end of each nasal catheter 910.
  • nasal catheters 910 will be placed a distance apart appropriate for the nares of the desired patient, and made a length appropriate for administration at the targeted tissues.
  • the dual-lumen mixing catheter 914 comprises an upper lumen 918 and a lower lumen 920 used to separately deliver the liquid and the gas,
  • This mixing catheter may be constructed as a single ended device, or made into a loop (not shown) similar to a standard nasal cannula for oxygen therapy.
  • the 'loop' configuration aids in placement on the patient, as it may be routed over and behind the ears to hold it in place.
  • the loop configuration also helps ensure equal flow when two nasal catheters are used.
  • Nasal catheter 910 is connected to mixing catheter 914 by a connecting tube 916.
  • Connecting tube 916 is a hollow, open ended tube for attaching nasal catheter 910 to mixing catheter 914 and for placing nasal catheter 910 in fluid comm unication with at least the lower lumen 920 of mixing catheter 914. It can he made from metal 'hypodermic' tubing, or a suitable plastic, As shown in Fig. 41 , the connecting tube 916 has an outer diameter sized to fit tightly in the lumen of nasal catheter 910 and thus form a seal between nasal catheter 910 and mixing catheter 914.
  • an over layer of glue or other compound such as silicone may be used to ensure a durable connection and smooth texture for patient comfort, in use, open ended, hollow tube 924 of connecting tube 916 places the lumen of nasal catheter 910 in fluid communication with the lower lumen 920 of mixing catheter 910.
  • the gas is supplied through the lower lumen 920 of the dual lumen tubing 914.
  • the gas flows through the lower lumen 920 and up through the lumen 924 of connecting tube 916 into the nasal catheter(s) 910.
  • the liquid is supplied through the upper lumen 918 of mixing catheter 914.
  • the liquid passes into the lumen 924 of connecting tube 916 via a small hole 922 drilled in the wall of connecting tube 916.
  • the inner diameter of the tube and the size of fluid hole 922 are important parameters in the optimization of the spray pa ttern,
  • the gas is moving at a high velocity and the liquid experiences high shear forces, breaking the stream into small droplets that then flow througli the lumen of nasal catheter 910 and are delivered as a spray to the patient's nasal cavity through the spray nozzle 15.
  • Fig. 42 illustrates an alternate embodiment of a mixing catheter.
  • the dual lumen tubing 914 is used as above, and catheter tip 12, including a spray nozzle 915 is also as previously described, in this embodiment, however, the mixing of the air and liquid occurs very near tip 912.
  • the liquid is delivered througli lower lumen 930 and the gas is delivered through upper lumen 928 of mixing catheter 914.
  • the nasal catheter is secured directly to an aperture in upper lumen 928 so that a small diameter liquid delivery tube 926 extending perpendicularly from lower lumen 930 of mixing catheter 914 is positioned inside the lumen of the nasal catheter 910.
  • Liquid tube 926 is a hollow, open ended tube extending through the lumen of nasal catheter 910 to the distal region of nasal catheter 10.
  • Liquid tube 926 has an outer diameter smaller than the inner diameter of nasal catheter 910 and smaller than the aperture connecting nasal catheter 910 to mixing catheter 914, In use, the liquid flows through lumen 927 of liquid tube 926 while the gas flows through upper lumen 928 and enters nasal catheter 910 via the annular space 929 between liquid tube 926 and the inside diameter of catheter 910. Turbulence and other flow effects, such as Bernoulli pressure, at the end of liquid tube 926 cause the fluid to be broken up into small droplets. This design requires less pressure to drive the liquid, and may aid in matching the liquid and gas flows.
  • Fig. 44 illustrates an alternative embodiment of a gas and liquid delivery system that may be attached the proximal end of the nasal catheter whereby the liquid and the gas are delivered to the catheter through their own rubes 950 and 952 and mixed at the point of administration to the patient, rather than prior to use. This ensures that even an unstable spray can be delivered to the desired region. Furthermore, because the liquid begins to evaporate immediately upon contact with the gas, mixing at the point of use in the patient will ensure efficient use of all available cooling. As seen in Fig, 44, the mixing device may comprise a mixing block 954 including at least two input flow channels 950 and 952 and a single output flow channel 956, Mixing block 954 may be machined from metal, plastic, or molded from plastic.
  • the two input flow channels 950 and 952 may be connected to two separate tubes containing a liquid and a compressed gas. Input channels 950 and 952 may then be joined in mixing block 954 so that the liquid and gas carried by the input tubes will be combined, after which the combined liquid/gas mixture may then flow through output channel 956.
  • the nasal catheter may be attached to output channel 956 for delivery of the combined liquid/gas mixture to the patient's nasal cavity.
  • Fig. 46 illustrates an alternative nasal catheter for cooling the nasal cavity with cold saline.
  • nasal catheter 990 includes an elongate tubular member, operably sized to extend into the patient's nasopharynx with expandable member 992 mounted on the distal end of catheter 990.
  • nasal catheter 990 is inserted into one of the patient's nostrils and positioned in the nasopharynx. Once positioned in the nasopharynx, expandable member 992 is expanded to conform to the nasopharynx and form a seal isolating the nasal cavity from the rest of the patient's airways.
  • saline is injected into one of the patient's nostrils and circulated though the nasal cavity to allow for rapid cooling of the patient's head.
  • Expandable member 992 prevents the saline from entering the patients other airways.
  • the saline may then be allowed to run out the patient's other nostril or may be suctioned from the patient's nasal cavity from a suction port (not shown) proximal to expandable member 992.
  • a second nasal catheter (not shown), also comprising an elongate tubular member with an expandable member mounted on the distal end, may be inserted in the patient's second nostril.
  • the balloons may be positioned on either side of the nasal cavity before the septum and expanded to isolate the nasal cavity from the rest of the patient's airways.
  • nasal catheter 990 includes an elongate tubular member, operably sized to extend into the patients nasopharynx and at least one expandable member 992 mounted near the distal end of the elongate tubular member and two expandable members 991 a-b mounted near the proximal end of catheter 990.
  • nasal catheter 990 is inserted into one of the patient's nostrils and positioned in the nasopharynx.
  • expandable member 992 is expanded to conform to the nasopharynx, and form a seal isolating the nasal cavity from the rest of the patient's airways and the expandable members 991 -b at.
  • the proximal end are positioned in the patients nostrils to seal the patient's nasal cavity, Altematively, as depicted in Fig. 48, the distal end may have two expandable members 992a-b that may be positioned at the posterior aspect of the nasal cavity to isolate the nasal cavity from the pharynx.
  • Catheter 990 also has openings 994 and 995 at the distal and proximal ends, respectively, to provide a breathing passage while the nasal cavity is sealed.
  • a cold fluid may be delivered to the nasal cavity via delivery lumen 997, which is in fluid communication with port 996.
  • a tube comprising a spray nozzle (not shown) may be inserted in the delivery lumen 997 to deliver a liquid spray to the nasal cavity.
  • Expandable members 992a-b and 991 a-b at the distal and proximal ends of catheter 990 preven non-vaporized fluid from leaking into the throat or running out the patient's nostrils.
  • the non-vaporized liquid may then be suctioned from the nasal cavity via suction lumen 999. which is in fluid communication with port 998.
  • This liquid may be discarded or altematively it may be recycled for successive use, Because there is a dedicated lumen for delivery and suction, however, delivery of the cooled liquid to the nasal cavity does not need to be interrupted.
  • a catheter with a flexible balloon having a chamber filled with a cooling liquid can be used to cool the brain via the nasal cavity.
  • assembly 200 includes flexible balloon 204 that is mounted circumferentially around catheter 202.
  • Catheter 202 has ports 21 1, 212 at the proximal and distal ends and lumen 210 extending therebetween that enables the patient to breathe while the catheter is in use.
  • Ports 21 1 , 212 and lumen 210 are in fluid communication with the patient's nasopharynx, pharynx, larynx, and/or esophagus.
  • Catheter 202 is approximately 8 cm in length, alternatively approximately 10 cm in length, alternatively approximately 12 cm in length, alternatively approximately 14 era in length, alternatively approximately 16 cm in length, alteraaxively approximately 18 era in length, alternatively approximately 20 cm in length.
  • Lumens 206, 208 are in fluid communication with the chamber of the flexible balloon 204 through, ports 207, 209 located at the distal ends. At their proximal ends, lumens 204, 206 are connected to a refrigerated pump (not shown) that is capable of recycling a cooling fluid through the chamber of the flexible balloon 204.
  • assembly 200 is inserted into the nasal cavity through, the patient's nostril such that flexible balloon 204 is within the nasal cavity and the distal end of catheter 202 extends through the nances to the
  • a cooling liquid or fluid ca then he used to inflate or infuse the chamber of flexible balloon 204 to a sufficient pressure such that flexible balloon 204 expands and is in contact with a substantial portion of the nasal cavity.
  • the cooling fluid may then be recirculated through the chamber of flexible balloon 204 via lumens 206, 208 and a refrigerated bath/pump (not shown).
  • the cooimg fluid can be withdrawn or suctioned, back out of flexible balloon 204 at a rate sufficient to induce or maintain a desired balloon pressure or brain temperature.
  • a second assembl can also be inserted into the other nostril such that maximum cooling can be obtained.
  • the cooling of the brain would occur by convection or heat exchange from the cold liquid in the chamber of the balloon to the warm nasal cavity.
  • Lumen 210 of catheter 202 allows the patient to breathe through his nose after the flexible balloon 204 is inflated.
  • other medical devices can be passed through lumen 210. These medical devices include, but are not limited to, oxygen tube, nasogastric tube, fiber optics, laryngoscope, pH probes, and esophageal manometry.
  • a flexible balloon having a chamber filled with a cooling liquid can be used to cool the brain via the nasal cavity.
  • assembly 250 includes flexible balloon 254 that has a chamber that is in fluid communication with lumens 256, 258 of elongate tubular members 264, 268 through ports 257, 259 located at their distal ends.
  • elongate tubular members 264, 268 may be connected to cooler 260 and pump 262 that infuse and/or recirculate the cooling liquid through lumens 256, 258 and the chamber of flexible balloon 254.
  • elongate tubular members 264, 268 may be connected to a refrigerated pump (not shown) that is capable of pumping and/or recirculating the cooling fluid,
  • assembly 250 is inserted into the nasal cavity through a nostril such that flexible balloon 254 is within the nasal cavity 270, A cooling fluid can then be used to inflate flexible balloon 254 to a sufficient pressure such that flexible balloon 254 expands and is in contact with a substantial portion of the nasal cavity.
  • the cooling fluid is then recirculated through flexible balloon 254 via lumens 256, 258, cooler 260, and pump 262.
  • the cooling fluid can be suctioned back out of flexible balloon 254 at a rate sufficient to induce or maintain a desired balloon pressure or brain temperature.
  • a second assembly can also be inserted into the other nostril such that maximum cooling can be obtained. The cooling of the brain would occur by convection or heat exchange from the co!d liquid in the balloon to the warm nasal cavity.
  • a flexible balloon having a chamber filled with a cooling liquid can be used to cool the brain via the nasal cavity.
  • assembly 700 includes flexible balloon 702 that has a chamber 703 that is in fluid communication with lumen 706 of elongate tubular member 708 through port 710 located at its distal end, At a point outside of chamber 703, elongate tubular member 708 branches into two elongate tubular members 715 and 720 having lumens 716 and 721 , respectively.
  • Elongate tubular members 720 and 715 are in communication with each other through pump 722, e.g., a piston pump, and cooler 724, located at or near the proximal ends of elongate tubular members 715 and 720.
  • Cooler 724 and pump 722 infuse and/or recirculate the cooling liquid through lumens 716 and 721 and the chamber of flexible balloon 254, This single lumen design may allow for faster inflation and deflation.
  • elongate tubular members 715 and 720 may be connected to a refrigerated pump (not shown) that is capable of pumping and/or recirculating the cooling fluid.
  • assembly 700 is inserted into the nasal cavity through a nostril such that flexible balloon 702 is within the nasal cavity.
  • a cooling fluid can then be used to inflate flexible balloon 702 to a sufficient pressure such that flexible balloon 702 expands and is in contact with a substantial portion of the nasal cavity.
  • the cooling fluid is then recirculated through flexible balloon 702 via lumens 706, 716, and 721 , cooler 722, and pump 724.
  • cooling liquid may be withdrawn from chamber 703 by having pump 722 withdraw the cooling liquid through lumens 706 and 721 of elongate tubular members 708 and 720, respectively.
  • Cooling liquid can then be pumped into cooler for further cooling and then pumped back into chamber 703 through lumens 716 and 706 of elongate tubular members 715 and 708.
  • a second assembly can also be inserted into the other nostril such that maximum cooling can be obtained. The cooling of the brain would occur by convection or heat exchange from the cold liquid in the balloon to the warm nasal cavity.
  • a flexible balloon having a chamber filled with a cooling liquid and a cold finger inside of a second balloon can be used to cool the brain via the nasal cavity
  • assembly 600 includes flexible balloon 602 that has chamber 603 that is in fluid communication with port 604.
  • a cooling liquid such as water or saline, can be infused into chamber 603 through port 604,
  • a second balloon 605 containing a cold probe 607 is contained within chamber 603 to cool the liquid inside flexible balloon 602.
  • a cooling agent such as Freon or other PFC, that is approximately Q°C, alternatively approximately -i 'C, alternatively approximately -2"C, alternatively approximately -3'C, alternatively between about -5°C and 5 ° C, alternatively between about -5 ° C and 0 ° C, will be flowed through cold probe 607.
  • the flow rate of the cooling agent will depend on the type used. The flow rate will be chosen to produce between about 150 and about 300 watts.
  • cold probe 607 may be connected to cooler 610, Second balloon 605 may be in fluid
  • second balloon 605 ma be in fluid communication with a compressor 612 through elongate tubular member 614 to circulate the cooling liquid,
  • Cold probe 607 may also have fins surrounding the cold probe (not shown) to increase the surface area of the probe, Alternatively, a heat pipe could be used in place of the cold probe.
  • the heat pipe could be filled with a gas such as Freon or ammonia, or alternatively, the heat pipe could be connected to a circulating cooling liquid reservoir or other cooling source (such as a block of ice).
  • assembly 600 is inserted into the nasal cavity through the patient's nostril such that flexible balloon 602 is within the nasal cavity.
  • a cooling fluid can then be used in inflate flexible balloon 602 to a sufficient pressure such that flexible balloon 602 expands and is in contact with a substantial portion of the nasal cavity.
  • the cooling agent will then be circulated into second balloon 605 via port 608 at the distal end of cold probe 607 and elongate tubular member 614.
  • the cooling agent may not be recirculated, but rather be vented out of a port in second balloon 605 (not shown).
  • the fluid in the balloon can be agitated to prevent freezing. This may be accomplished by moving cold probe 607 or pulsing the infusion of the cooling agent into second balloon 605.
  • a second assembly can also be inserted into the other nostril such that maximum cooling can be obtained. The cooling of the brain would occur by con vection or heat exchange from the cold liquid in the balloon to the warm nasal cavity.
  • a flexible balloon having a chamber filled with a cooling liquid and a cold finger can be used to cool the brain via the nasal cavity.
  • assembly 650 includes flexible balloon 652 that has chamber 653 that is in fluid communication with port 654 containing a filter 656.
  • a cooling liquid such as water or saline, can be infused into chamber 653 through, lumen 658 of elongate tubular member 659.
  • a cooling agent such as Freon or other PFC, that is approximately O'C, alternatively approximately -VC, alternatively approximately - 2'C, alternatively approximately ⁇ 3 "" C, alternatively between about -5°C and 5°C, alternatively between about -5 ° C and 0 ° C, will be flowed through cold probe 657.
  • cold probe 657 may be connected to cooler (not shown).
  • the cooling agent will flow out of port 658 of cold probe 657 and produce gas bubbles 660 in the cooling liquid in chamber 653, thereby cooling the liquid further and agitating the liquid to aid in mixing the liquid throughout chamber 653.
  • the gas bubbles can. exit chamber 653 throisgh port 654 with air venting filter 656, which allows for the release of gas and not liquid.
  • an additional elongate tubular member (not shown) can be inserted into flexible balloon 652 such that a lumen of the elongate tubular member is in fl uid communication with chamber 653 of balloon 652.
  • An additional gas such as oxygen or nitrogen, can be delivered into the cooling liquid to aid in the mixing and agitation of the cooling liquid within the chamber,
  • assembly 650 In use, with the patient lying on his back, assembly 650 is inserted into the nasal cavity through the patient's nostril such that flexible balloon 652 is within nasal cavity 670.
  • a cooling fluid can then be used in inflate flexible balloon 652 to a sufficient pressure such that flexible balloon 652 expands and is in contact with a substantial portion of nasal cavity 670.
  • the cooling agent will flow out of port 658 of cold probe 657 and produce gas bubbles 660 in the cooling liquid in chamber 653, thereby cooling the liquid further and agitating the liquid to aid in mixing the liquid throughout chamber 653,
  • the gas bubbles can exit chamber 653 through port 654 with air venting filter 656, which allows for the release of gas and not liquid. Additionally, the fluid in the balloon can be agitated to prevent freezing.
  • Flexible balloons for use in the nasal cavity are sized such that upon inflation, they are capable of making good contact with the surfaces of the nasal cavity, including the portion of the cavity that lies posterior to the cavernous sinus.
  • the length of the flexible balloon will depend upon the size of the nasal cavity and may be less than 15 em long, alternatively less than 14 cm long, alternatively less than 13 cm long, alternatively less than 12 cm long, alternatively less than 1 1 cm long, alternatively less than 10 cm long, alternatively less than 9 cm long, alternatively less than 8 cm long.
  • the flexible balloons may also have the shape of the nasal cavity. Alternatively, as seen in Fig.
  • flexible balloon 750 may have a shape containing multiple fingers such that, upon inflation, one or more fingers will have the opportunity to extend into and fill the meatus (superior, middle, and/or inferior) to maximize contact with the tissues in the nasal cavity.
  • the flexible balloon may have multiple lobes to accomplish the same purpose of extending into and filling the meatus.
  • the flexible balloons are also preferably oversized and made of a soft, conformable, elastomeric material to provide maximum surface contact with the nasal cavity.
  • the assemblies may also include a check valve (not shown) that will release fluid, thereby reducing the pressure of the flexible balloons when they reach a certain pressure.
  • the flexible balloons may be made of a porous material that allows for the controlled release of drugs to the nasal ca vity.
  • materials for the elastomeric, flexible balloons include, but are not limited to, uretbanes, vinyl (PVC), silicone.
  • non-elastic materials include, but are not limited to, mylar, polyethylene, polypropylene, polystyrene, and polyvinylacetate.
  • the pressure in these flexible balloons for use in the nasal cavity can oscillate between lower and higlier pressures, in other words, the fluid can be infused to fill the chamber defined by the balloon either slowly or quickly.
  • the fluid can be infused to fill the chamber defined by the balloon either slowly or quickly.
  • Extended periods at higher pressures may not be desirable due to possible problems with stopping blood flow in the surrounding tissue. Additionally, the act of pulsing the liquid would result in increased circulation of the liquid.
  • Rapid pulsing for the purposes of mixing the liquid within the balloon chamber, could range from about 0.5 to about 200 Hz, alternatively from about 1 to about 150 Hz, alternatively from about ⁇ to about 100 Hz, alieraatively from about 10 to about 100 Hz, alternatively from about 25 to about 100 Hz, Slower pulsing could be used to affect physiologic responses, such as deflating the balloon to allow blood flow to resume circulation in the cooled area. Slower pulsing could range from about one inflation per second to about one inflation per 10 minutes, alternatively from about one inflation per second to about one inflation per 5 minutes, alternatively from about one inflation per second to about one inflation per 3 minutes.
  • the balloon could be inflated approximately once every 30 seconds, alternatively once every 1 minute, alternatively once every 2 minutes, alternatively once every 3 minutes, alternatively once every 4 minutes, alternatively once every 5 minutes, alternatively once every 6 minutes, alternatively once every 7 minutes, alternatively once every 8 minutes, alternatively once every 9 minutes, alternatively once every 10 minutes.
  • the balloon could remain inflated for approximately 1% of the cycling period, alternatively approximately 5% of the cycling period, alternatively approximately 10% of the cycling period, alternatively approximately 20% of the cycling period, aftematively approximately 30% of the cycling period, alternatively approximately 40% of the cycling period, alternatively approximately 50% of the cycling period.
  • the chambers of the flexible balloons may be filled with foam, e.g., open ceil foam.
  • the foam e.g., open-cell foam may be surrounded by a membrane.
  • the open-cell foam will aid in conforming the balloon to the applicable cavity, for example, the nasal cavity, while also helping to distribute cooling.
  • the foam may be made from urethane, latex, rubber, ethylene vinyl acetate (EVA), and other open-cell materials.
  • the foam that is contained either within the flexible balloon or the membrane will be compacted using a vacuum source. After the compacted foam has been inserted into the desired body- cavity, e.g., the nasal cavity, the vacuum will be released and the balloon will be allowed to expand to contact the surrounding tissue. Saline, water, PFC, refrigerant, anti-freeze solution, other cooling fluid, or a combination thereof can then be circulated into the open-cell foam to cool the surrounding tissue.
  • a cooling liquid is circulated into and out of the nasal cavity. The following calculations are done assuming that the chilled fluid will be an aqueous fluid.
  • the liquid will enter the nasal cavity at a temperature well below body temperature, and exit at a warmer temperature.
  • the warmthing of the water will be equal to the cooling of the body, so the calculations for heat added to the water is the same as that for heat removed from the body.
  • Tl the temperature of the liquid at administration T2 - the temperature to which the liquid is warmed
  • the cooling of the whole body can be calculated using the same equation as above.
  • the heat capacity of the human body is generally accepted to be 0.85 cal/gm °C.
  • other sources of heat entering or leaving the body, and heat generated in the body are neglected, as it is likely those aspects balance out in a stable patient. Cooling therefore reduces to the equation below.
  • the temperature change is calculated below to be 0,93 °C per hour, which is close to the target cooling rate for patients.
  • WBC (°C/kr) AT(liquid, °C) * Flow rate (ml/min) / (Patient wt(kg) * 143) or
  • the surface of the balloon may be treated or modified to maximize thermal conductance
  • a gel may also be optionally applied to the exterior of flexible balloons 204, 254 before insertion into the nasal cavity.
  • the gel would preferably have good thermal conduction properties and be a better conductor than air. Additionally, the gel could also act as a lubricant to assist in the insertion. The gel would help the flexible balloon make better contact with the mucous membrane and would also fill some of the air space in the nasal, cavity, which should increase effective surface area.
  • the gel may include, but is not limited to, any aqueous gel, a poloxamer-based gel, a cellulose gel (such as KY jelly), a nasal -packing jelly, a hydrogel (such as MeroGel or GelFilm), or a thermal gel.
  • aqueous gel such as a poloxamer-based gel, a cellulose gel (such as KY jelly), a nasal -packing jelly, a hydrogel (such as MeroGel or GelFilm), or a thermal gel.
  • sponges may be attached to the surface of the balloon. Sponges, such as PVA sponges, are commonly used as packing material in noses and will conform to the shapes of the nasal cavity when wet.
  • a hydropbilic coating may also be applied to the outer surface of the balloon to prevent beading on the outside,
  • Advantages of this apparatus and method include rapid circulation of the cooling fluid, rapid transfer of heat from the flexible balloon to the membranes of the nasal cavity, and flexibility in choice of coolant because the fluid is contained. Heat is transferred through the mucosa from the pool of blood in the cavernous sinus to the cooling fluid in the flexible balloon, thereby cooling the pool of blood in the cavernous sinus. Consequently, the blood in the carotid arteries, which runs through the cavernous sinus, is also cooled as it travels to the brain. In particular, the maximal heat exchange will likely be with the ascending carotid arteries immediately before entry into the intracrani al space and the terminal portion of the extracranial internal carotid artery.
  • thermoconducting gel 850 may be inserted info the nasal cavity of a patient to substantially fill the cavity.
  • Cooling device 852 such as a cold probe or heat pipe, can then be directly inserted into gel 852 to cool gel 852, thereby moling the nasal cavity.
  • the conductive device could be a metal, such as copper.
  • conductive device 852 may be a probe through which a chilled fluid is circulated, a probe in which a fluid undergoes a phase change, or a heat pipe, which is a sealed system utilizing an internal fluid that boils on one end and condenses on the other end in order to transmit heat, in the case of the probe with the fluid undergoing a phase change, the fluid may have a boiling point below body temperature, such as a perfluorocarbon or Freon,
  • external cooling source 854 such as a refrigeration system, thermoelectric heat pump, ice baih, or evaporative cooler, will be connected to the proximal end of the probe. Consequently, a cerebral temperature of the patient can be reduced by at least 1 ° C in one hour, alternatively at least 2 ° C in one hour, at least 3 ° C in one hour.
  • a sponge may be inserted into the nasal cavity of a patient to substantially fill the cavity.
  • the sponge could surround the outside of a balloon to help fill the nasal cavity.
  • the sponges may help to fill the back of the mouth and come into intimate contact with the soft palate and upper pharynx.
  • the sponge could be inserted into the nasal cavity alone.
  • the sponge could be connected to an inlet and outlet tubular member to allow for circulation of fluids within the sponge.
  • the increased surface area of the sponge would allow for better contact with the interior surfaces of the nasal cavity.
  • the sponges could be designed with finger or hair-like extrusions to increase the surface area, thereby increasing contact with the interior surfaces of the nasal cavity.
  • a hollow tube could be inserted through the sponge and/or balloon to facilitate breathing,
  • a modified nasogastric tube with a flexible balloon having a chamber filled with a cooling liquid may be used to cool the brain.
  • the assembly includes nasogastric tuber 356 having lumen 357.
  • flexible balloon 354 that is mounted circurnferentially around nasogastric tube 356 for the length of the esophagus, and elongate tubular member 360 having lumen 362.
  • Nasogastric tube 356 is approximately 0.8 m in length, alternatively approximately 1 m in length, alternatively approximately 1.2 m in length, alternatively approximately 1.4 m in length, alternatively approximately 1.6 m in length, alternatively approximately J .8 m in length, alternatively between about 0.8 m and 3.8 m in length.
  • An additional flexible balloon 358 may be attached at the distal end of the nasogastric tube 356. Flexible balloon 358 would be in fluid communication with lumen 357 of nasogastric tube 356 and a chamber of flexible balloon 354 and, upon expansion, would be sized to substantially fill the patient's stomach.
  • flexible balloon 354 may be sized and shaped to substantially fill the patient's stomach upon expansion.
  • elongate tubular member 360 and nasogastric tube 356 are connected to a pump and a cooler (not shown) or a refrigerated pump (not shown) that is capable of infusing and/or recycling a cooling fluid through flexible balloons 354, 358,
  • Flexible balloons 354, 358 are sized that upon inflation, they are capable of making good contact with the surfaces of the adjacent anatomy, e.g., nasal cavity, esophagus, or stomach.
  • Flexible balloons 354, 358 are also preferably oversized and made of a soft, conformable, elastomeric material to provide maximum surface contact with the anatomy in which they are positioned. Flexible balloons 354, 358 may also include a check valve (not shown) that will release fluid, thereby reducing pressure of flexible balloons 354, 358 when they reach a certain pressure. Optionally, all or a portion of flexible balloons 354, 358 may be made of a porous material that allows for the controlled release of drags.
  • the patient is intubated and the assembly is insetted through a patient's nostril, down the back of the throat, through the esophagus, and into the stomach.
  • the assembly is positioned such that flexible balloon 354 is located in the nasal cavity and the esophagus and flexible balloon 358 is located in the stomach.
  • a cooling fluid can then be infused into flexible balloons 354, 358 to expand the balloons such that they substantially fill and contact the nasal cavity, esophagus, and stomach, respectively.
  • the cooling fluid could be pumped in through nasogastric tube 354 and suctioned out of elongate tubular member 360 at a rate sufficient to induce or maintain a desired pressure in the flexible balloons 354, 358 or a desired brain temperature.
  • the cooling fluid may then be recirculated through flexible balloons 354, 358 via nasogastric tube 356, shaft 360, and a refrigerated pump (not shown),
  • a modified laryngeal mask having a flexible balloon having a chamber filled with a. cooling liquid can be used to cool the brain.
  • the laryngeal mask 320 includes an elongate tubular member 322 having a proximal end, a distal end, and a lumen 323 therebetween that communicates with ports at the proximal and distal ends.
  • the elongate tubular member 322 is preferably curved to match the anatomy of the oropharynx.
  • Toroidal balloon 324 has a chamber, and surrounds port 325 at the distal end of elongate tubular member 322, wherein the chamber is in fluid communication with lumens 326, 328 of elongate tubular members 327, 329.
  • lumens 326, 328 may be part of elongate tubular member 322.
  • Elongate tubular members 327, 329 are also connected to a pump and cooling unit (not shown) or a refrigerated um (not shown) that is capable of infusing and/or recycling a cooling fluid through flexible toroidal balloon 324.
  • the cooling fluid may include, but is not limited to, water, saline. PFC, anti-freeze solution, or a combination thereof.
  • the modified laryngeal mask may also include an additional balloon 330 that is located on the distal region of the backside of elongate tubular member 322. wherein a chamber of additional balloon 330 is in fluid communication with lumens 332, 334.
  • Lumens 332, 334 may be part of elongate tubular member 322 or part of separate elongate tubular members. Additionally, the camber of additional balloon 330 may alternatively be in fluid communication with lumens 326, 328 (not shown). Lumens 332, 334 would also be connected to a pump and cooling unit (not shown) or a refrigerated pump (not shown) that is capable of recycling the cooling fluid through flexible balloon 330.
  • the modified laryngeal mask 320 is positioned in the patient to sit tightly over the larynx. Toroidal balloon 324 is emptied before insertion and lubricated with a gel. In addition to being a good lubricant, the gel would also preferably have good thermal conduction properties and be a better conductor than air.
  • the gel may include, but is not limited to, a poloxomer-based gel (such as Y jelly) or a packing jelly.
  • the neck of the patient is extended and the mouth is opened widely.
  • the apex of the laryngeal mask 320, with the port or opening 325 pointing downwards toward the tongue, is pushed backwards toward the uvula.
  • Elongate tubular member 322 follows the natural bend of the oropharynx and the mask comes to rest over the puriform fossa.
  • a cooling fluid can then be used to infuse and/or inflate toroidal balloon 324 to a sufficient pressure such that toroidal balloon 324 sits tightly over the larynx and is in contact with the epiglotis.
  • the cooling fluid may then be recirculated through toroidal balloon 324 via lumens 326, 328, cooler (not shown), and pump (not shown). Additionally, the cooling fluid can be withdrawn or suctioned out of toroidal balloon 324 at a rate sufficient to induce or maintain a desired balloon pressure or brain temperature.
  • the airway is protected by the elongate tubular member 322.
  • a cooling pad may be used to cool the brain via the oral cavity.
  • the assembly 400 includes a.
  • tubular members 403, 405 are connected to cooler 410 and pump 412, Alternatively, tubular members 403, 405 may be connected to a refrigerated pump (not shown) that is capable of infusing and/or recirculating cooling fluid.
  • the pad may be about 2.5 cm in length, alternatively about 3 cm in length, alternatively about 3.5 em in length,
  • the assembly 400 is inserted into the oral cavity through the month such that the flexible balloon or pad 402 covers the retromandibular area or peritonsillar region.
  • a cooling fluid can then be infused into the chamber of flexible balloon or pad 402 to expand it to a sufficient pressure such that flexible balloon or pad 402 is substantially in contact with the retromandibular area or peritonsillar region.
  • the cooling fluid may then be recirculated through flexible balloon 402 via lumens 404, 406, using pump 432 and cooler 410 or a refrigerated pump.
  • the cooling fluid can also be withdrawn or suctioned out of the flexible balloon 402 at a rate sufficient to induce or maintain a desired balloon pressure or brain temperature. Cooling of the brain may be achieved through convection or heat transfer between flexible balloon or pad 402 and the extracranial carotid artery.
  • the cooling fluid used with these inventions may include, but is not limited to, water, saline, PFC, anti-freeze solution, or a combination thereof.
  • the temperature of the cooling fluid will preferably be below body temperature.
  • the temperature of the cooling fluid may be between about 37 ° C to about - 20 ° C, alternatively between about 30°C to about - 20"C, alternatively between about 20 ° C to about - 20°C, alternatively about 0°C, alternatively about 5°C ? alternatively about -5 ° C, alternatively between about -5°C to about 10°C, alternatively between about -5 ° C to about 5°C, alternatively between about 0°C to about 5°C.
  • the saline When saline is used as the cooling fluid, the saline will preferably be about Q°C.
  • the cooling fluid should recirculate at a fast enough rate to maintain the low temperatures within the balloon.
  • the flow rate of the cooling liquid may be between about 5 and about 5 L/min, alternatively between about 100 and about 400 ml/min, alternatively between about 200 and about 300 ml min, alternatively between about 150 to about 200 ml/min.
  • a gel may also be optionally applied to the exterior of flexible balloons before insertion into the oral cavity.
  • the gel would preferably have good thermal conduction properties and be a better conductor than air. Additionally, the gel could also act as a lubricant to assist in the insertion.
  • the gel may include, but is not limited to, any aqueous gel, a poloxamer-based gel, a cellulose gel (such as KY jelly), a nasal -packing jelly, or a thermal gel.
  • sponges may be attached to the surface of the balloon. Sponges, such as PVA sponges, are commonly used as packing material and will conform to the shapes of the oral cavity when wet.
  • the sponges could be designed with finger or hair-like extrusions to increase the surface area, thereby- increasing contact with the interior surfaces of the oral cavity.
  • the sponges may fill the back of the mouth and allow for maximal cooling at the soft palate and retropharynx.
  • a hydrophiltc coating may also be applied to the outer surface of the balloon to prevent beading on the outside,
  • a tube may also be inserted to allow breathing.
  • the invention includes a liquid and gas delivery system for the delivery of a fixed, or substantially fixed, ratio of liquid and gas.
  • gas flow meter 505 can be set to deliver a set flow of gas to mixing hub or manifold 510 through gas line 507.
  • gas will also flow to bottle 520 through gas line 508.
  • Gas lines 507 and 508 may also comprise a single branched tube (not shown). As reservoir or bottle 520 becomes pressurized, liquid 525 in bottle 520 will flow through line 530 to manifold 510.
  • Flow restrictors 535 and 536 can be set to each allow a specific flow of liquid for a specific pressure of gas. For example, flow restrictor 535 may allow a higher flow rate than flow resirictor 536 for a specific pressure of gas. Stopcock 532 can be connected to line 530.
  • Stopcock 532 is used to direct flow either to restrictor 535 or 536 or can be used to stop liquid flow altogether.
  • Filter 537 can also be placed in line 530 before mixing manifold 530.
  • An overpressure safety device 515 within gas flow meter 505 can stop the flow of gas if a certain pressure is detected. Activation of the overpressure safety device 515 would switch valve 570 to stop gas flow and vent gas lines 507 and 508. Therefore, the pressure in gas lines 507 and 508 and bottle 520 will all be reduced to zero. Therefore, the flow of liquid will also be stopped by the activation of safety device 515.
  • the gas could be air, oxygen, or a combination thereof.
  • the liquid could include a
  • perfluorocarbon such as perfluorohexane, perfluoropentane, or 2 -m ethyl - perfiuoropentane.
  • Mixing manifold 510 can be connected to catheters 540 and 545, each containing mul tiple deli very ports 541 and 546 for delivery of the gas and l iquid mixture to, for instance, the nasal cavity.
  • Liquid can flow from line 530 into liquid lumens 572 and 574 of catheters 540 and 545 through ports 560 and 562, respectively.
  • gas can. flow from line 507 into lumens 542 and 547 of catheters 540 and 545 through ports in the distal ends of the respective catheters.
  • the gas and liquid can later be mixed and delivered to the nasal cavity through the multiple ports 541 and 546 as a nebulized spray, as described above.
  • Pressure in the nasal cavity can be measured through pressure lines 51 1 and 512, which are in communication with ports 565 and 566 located near the distal ends of catheters 540 and 545 through pressure lumens 576 and 578 and ports 561 and 563, respectively.
  • a separate catheter could be inserted to measure the pressure in the nasal cavity (not shown). If a pressure measured in the nasal cavity in which the liquid and gas is being delivered is found to be too high, overpressure safety device 515 will stop the flow of gas, and consequently, the flow of liquid, to the nasal cavity. Additionally, the stopcock could be closed when it is desired to only deliver a gas, for instance, oxygen, rather than cool the patient.
  • the mixing catheter may further include a liquid delivery system for using the pressure from the compressed gas source to deliver the liquid to the nasal catheter, in this device, both the gas and the liquid are delivered strictly using the pressure from the compressed gas source without the use of pumps or electronics.
  • inlet valve 964 is connected to compressed gas source 960, for example, oxygen or an oxygen and air mixture regulated to about 50 psi. Inlet valve 964 blocks or allows the pressurized gas into the rest of the system. When inlet val ve 964 is in the "blocked" position, valve 964 also may vent pressure from the system. Pressure regulator 962.
  • the inlet valve When the inlet valve is in the "allow” position, the gas flow splits in two directions, i.e., flow is connected to the gas flow channel 978 of the dual lumen tubing (not shown) and flow is also directed to fluid reservoir container 968 that is designed to hold the desired dose of a liquid.
  • the fluid control reservoir 968 is rated to withstand the pressure of the compressed gas, for example the fluid control reservoir may be a poly ethylene teraphalate (PET) container tested to pressures in excess of 150 psi. in addition, a burst disk or relief valve 966, set at a value exceeding the expected operating pressure, for example 60 psi, alternatively 70 psi, alternatively 80 psi, alternatively 90 psi, may be added to the fluid reservoir container as a safety means for venting gas in the event of over pressurization.
  • the pressurized gas flows into fluid reservoir 968, the fluid is routed though an outlet port in the reservoir that is in fluid communication with liquid channel 980 of the dual lumen tubing (not shown).
  • the outlet port may include fluid flow controlling device 972, such as a needle type valve or a variable diameter aperture, to adjust the flow rate of fluid into liquid channel 980 of the dual lumen tubing, in addition, gas How channel 978 of the dual lumen tubing may also include flow controlling device 970, such as a needle type valve or a variable diameter aperture, to adjust the flow rate of gas into the gas channel of the dual lumen tubing.
  • the flow control valves 970 and 972 of the gas and liquid channels may be independently controlled by the operator to allow full flexibility in varying the gas and/or liquid flow to optimize the gas/liquid flow ratio.
  • the gas and liquid flow control valves 970 an 972 may have fixed orifices that produce a known constant flow for the gas and the liquid, or alternatively, the flow control valves 970 and 972 may include a selector (not shown) that would allow the operator to choose one of several sets of orifices in order to provide the operator with a number of choices for the flow, for example low flow, medium flow, high flow, induction, and maintenance flow rates.
  • each set point on the selector would use a predetermined orifice for the gas flow and a matched orifice for the liquid such that the gas/liquid flow rates and ratios would be optimized for each condition
  • the flow rate generated by the fixed orifices may be further altered while maintaining the constant gas/liquid ration, by using pressure regulator to regulate the input pressure of the gas source.
  • liquid and gas flow meters 974 and 976 may be placed in the liquid and gas flow channels to further monitor and regulate the liquid and gas flow rates
  • Flow meters 974 arid 976 may be any standard flow technology such as turbines, paddlewheels, variable area Rota meters or mass flow meters
  • in-line filters (not shown) may be placed in both the gas and liquid channels to prevent particulate matter from being introduced to the patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)

Abstract

L'invention concerne des procédés et dispositifs de refroidissement systémique et cérébral. Le dispositif comprend un élément tubulaire allongé qui présente des première et seconde lumières afin de transporter un liquide et un gaz et une pluralité d'orifices de distribution. Une pluralité de canaux de mélange s'étend entre les orifices de distribution et la première lumière. Une pluralité de tubes de connexion s'étend entre la pluralité de canaux de mélange et la seconde lumière. Un commutateur est connecté fonctionnel à la première lumière et fonctionne pour établir et interrompre le flux du liquide, depuis une source de liquide jusqu'à la première lumière. En utilisation, le dispositif est inséré dans la cavité nasale d'un patient et un gaz sensiblement sec est distribué sur la surface de la cavité. Un réfrigérant liquide atomisé peut également être distribué sur la surface de la cavité en association avec le gaz sec. Le gaz sec améliore l'évaporation du réfrigérant atomisé, fournissant ainsi un refroidissement supplémentaire provenant de la perte de chaleur lorsqu'elle s'évapore.
PCT/US2013/032379 2012-03-19 2013-03-15 Procédés et dispositifs de refroidissement systémique et cérébral non invasif alternant une brume de liquide/du gaz pour l'induction et de gaz pour la maintenance WO2013142365A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/423,561 US9358150B2 (en) 2005-05-13 2012-03-19 Methods and devices for non-invasive cerebral and systemic cooling alternating liquid mist/gas for induction and gas for maintenance
US13/423,561 2012-03-19

Publications (1)

Publication Number Publication Date
WO2013142365A1 true WO2013142365A1 (fr) 2013-09-26

Family

ID=49223269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/032379 WO2013142365A1 (fr) 2012-03-19 2013-03-15 Procédés et dispositifs de refroidissement systémique et cérébral non invasif alternant une brume de liquide/du gaz pour l'induction et de gaz pour la maintenance

Country Status (1)

Country Link
WO (1) WO2013142365A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112755373A (zh) * 2021-01-12 2021-05-07 天津中医药大学 一种鼻塞
WO2021094381A1 (fr) * 2019-11-13 2021-05-20 TEQCool AB Dispositif et méthode de régulation de la température cérébrale

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6983749B2 (en) * 2001-12-04 2006-01-10 Minnesota High-Tech Resources, Llc Inducing hypothermia and rewarming using a helium-oxygen mixture
WO2010065616A1 (fr) * 2008-12-02 2010-06-10 Thermocure, Inc. Systèmes et procédés pour la distribution d'un gaz respiratoire comprenant de fines particules de glace
US20100312315A1 (en) * 2007-01-26 2010-12-09 Alex Etwil Apparatus and Method for Cooling the Brain Using a Gas
US20110028938A1 (en) * 2005-05-13 2011-02-03 Denise Barbut Methods and devices for treatment of migraines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6983749B2 (en) * 2001-12-04 2006-01-10 Minnesota High-Tech Resources, Llc Inducing hypothermia and rewarming using a helium-oxygen mixture
US20110028938A1 (en) * 2005-05-13 2011-02-03 Denise Barbut Methods and devices for treatment of migraines
US20100312315A1 (en) * 2007-01-26 2010-12-09 Alex Etwil Apparatus and Method for Cooling the Brain Using a Gas
WO2010065616A1 (fr) * 2008-12-02 2010-06-10 Thermocure, Inc. Systèmes et procédés pour la distribution d'un gaz respiratoire comprenant de fines particules de glace

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WOLFSON, MR ET AL.: "Intranasal perfluorochemical spray for preferential brain cooling in sheep.", NEUROCRITICAL CARE, vol. 8.3, 2008, pages 437 - 447 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021094381A1 (fr) * 2019-11-13 2021-05-20 TEQCool AB Dispositif et méthode de régulation de la température cérébrale
CN112755373A (zh) * 2021-01-12 2021-05-07 天津中医药大学 一种鼻塞
CN112755373B (zh) * 2021-01-12 2022-10-04 天津中医药大学 一种鼻塞

Similar Documents

Publication Publication Date Title
US10561527B2 (en) Methods and devices for non-invasive cerebral and systemic cooling alternating liquid mist/gas for induction and gas for maintenance
EP1888156B1 (fr) Dispositifs pour refroidissement cerebral et systemique non invasif
US9775741B2 (en) Methods and devices for non-invasive cerebral and systemic cooling
US20090234325A1 (en) Methods and devices for non-invasive cerebral and systemic cooling
US10076441B2 (en) Devices for cooling the nasal cavity
WO2008063179A1 (fr) Procédé et dispositif pour un refroidissement cérébral et systémique non invasif
US8308786B2 (en) Methods and devices for non-invasive cerebral and systemic cooling via the nasal cavity
AU2016203347B2 (en) Method And Device For Non-Invasive Anatomical And Systemic Cooling And Neuroprotection
US6983749B2 (en) Inducing hypothermia and rewarming using a helium-oxygen mixture
EP2736581A2 (fr) Systèmes, dispositifs et procédés non invasifs de refroidissement cérébral sélectif
WO2013142365A1 (fr) Procédés et dispositifs de refroidissement systémique et cérébral non invasif alternant une brume de liquide/du gaz pour l'induction et de gaz pour la maintenance

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13764068

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13764068

Country of ref document: EP

Kind code of ref document: A1